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ABSTRACT 
 
Background: Metastasis is a highly complex process and the detailed molecular 
mechanisms are not fully understood.  In recent years, a role for chemokine receptors 
in tumour growth and metastasis has emerged.  CCR7 is involved in the regulation of 
leukocyte homing to regional lymph nodes.  Interestingly, invasion of lymphatic 
vessels by tumour cells and their migration towards draining lymph nodes resembles 
this process.  Several lines of evidence exist to implicate CCR7 in lymph node 
metastasis.  In contrast, little is known about the contribution of CCRL1 to lymph node 
metastasis. 
Aims: The main objective was to investigate CCR7-driven metastasis in the lymph 
node and to assess whether CCRL1 expression affects this process. 
Methods: Tumour growth was assessed through the immunofluorescent staining of 
murine lymph node sections.  Tumour kinetics was assessed by inoculation of WT and 
CCRL1-knockout mice with CCR7-expressing B16 melanoma cells. 
Results: CCR7-expressing B16 melanoma establishes in the B cell areas of the lymph 
node and suppresses both CCRL1 and CCL21 expression in the sinus.  Depletion of 
CCRL1 does not affect metastatic growth. However, CCRL1-knockout mice develop 
primary melanoma tumours with enhanced kinetics. 
Discussion: These findings provide further insight into the role of chemokine receptors 
in melanoma metastasis. 
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1. INTRODUCTION 
1.1 Cutaneous Melanoma 
   Cutaneous melanoma is characterised by the malignant growth of melanocytes, the 
melanin-producing cells of the skin.  Of all forms of skin cancer, malignant melanoma 
remains the most fatal and is one of the most common malignancies among Caucasians 
(1). An estimated 47 000 cases are diagnosed every year in the United States alone (2) 
and the overall incidence appears to be increasing at a rate faster than for any other 
cancer type(3).  Treatment for primary melanoma typically involves surgical excision 
of the tumour mass and, if treated early, is associated with a 5-year survival rate of 
approximately 81-93% (4).  
1.1.1 Metastatic Melanoma 
   Metastatic melanoma is considered to be one of the most treatment-refractory 
cancers and is the leading cause of death from melanoma.  Despite therapeutic attempts 
it remains virtually impossible to eradicate, with a median overall survival for patients 
diagnosed with metastatic melanoma of just 8-9 months (5).  Until recently, very few 
therapies have been approved for the treatment of metastatic melanoma.  Mono-
chemotherapy with Dicarbazine has long been the first-line treatment for metastatic 
melanoma but, to date, has not been shown to improve overall survival rates (6).  High-
dose IL-2 is an additional FDA-approved therapy.  Although administration of high-
dose IL-2 can result in a durable response, this has only been the case for a very 
limited number of patients (6). 
1.2 The Metastatic Cascade 
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   Metastasis is a highly organised process that arises following the dissemination and 
growth of cancerous cells from the original site to one, or more, distal sites within the 
human body.  The ensuing secondary tumours are responsible for approximately 90% 
of human cancer-related deaths(7).  The process itself is exceedingly complex and 
comprises a series of sequential steps.  The formation of new blood and lymphatic 
vessels via processes known as angiogenesis and lymphangiogenesis respectively is 
essential for the growth of the primary tumour.  Moreover, they provide a means of 
escape for the tumour cells from primary sites, which may then colonize secondary 
sites.   
   As a result of changes in the expression of genes as well as potential epigenetic 
changes, the primary tumour cells undergo extensive cytoskeletal remodelling.  This 
consequently leads to a breakdown in cell-to-cell adhesion, thus enabling the tumour 
cells to shed away from the primary tumour mass and to invade nearby blood vessels – 
known as intravasation.  Alternatively, the cells may invade surrounding lymphatic 
vessels.  Once in the circulation, surviving tumour cells will become arrested, mainly 
due to receptor-mediated signalling but also due to size restrictions (8). These arrested 
cells will then extravasate into the surrounding tissue, where they must proliferate in 
order to form micrometastases.  On the other hand, tumour cells that enter the 
lymphatic vessel may settle and initiate tumour growth within the regional draining 
lymph node(s). 
   Clinical observations of cancer patients and in vivo experimental models have 
demonstrated that certain types of cancers have a tendency to form metastases in 
specific organs (9).  For instance, malignant melanoma preferentially metastasises to 
the regional lymph nodes draining primary tumour sites.  It has been suggested that up 
to 60% of melanomas cause lymph node metastases (1).  Such metastases have a major 
 15 
impact on patient prognosis as 75-80% of patients with lymph node involvement also 
exhibit distant metastases (10,11).  Although much progress has been made in the field 
of cancer research, the detailed molecular mechanisms by which tumour cells 
metastasise to the lymph nodes remain elusive.  There is now a growing body of 
evidence to support a role of chemokine receptors and their corresponding ligands in 
tumour growth, survival and metastasis (8). 
1.3 Chemokines and Their Receptors 
Chemokines represent an important superfamily of small chemotactic proteins (8-11 
kDa (8)), which are further classified in to 4 subgroups (C, CC, CXC, CX3C) based 
upon the relative position of conserved cysteine residues located near their amino 
termini (12).  A diverse class of cell-surface receptors, known as the seven-
transmembrane domain G-protein-coupled receptors (GPCR), mediate chemokine 
signalling.  At present, almost 50 chemokines (13) and 19 different receptors (12) have 
been identified.  Through various chemokine-GPCR combinations, chemokines are 
able to evoke a number of distinct cellular responses including proliferation, 
differentiation and angiogenesis (8,12).  Their best known function, however, is to 
promote the directional migration of leukocytes towards extravascular target tissues, 
both under steady-state (‘homeostatic’ chemokines) and inflammatory (‘inflammatory’ 
chemokines) conditions.  Upon GPCR activation, leukocytes assume a polarised 
morphology, owing to the reorganisation of integrins and the actin cytoskeleton (12).  
These polarised cells form sheet-like lamellipodia at the leading edge and contractile 
acto-myosin filaments at the trailing edge, both of which drive cell locomotion (12).   
Chemokine receptors are also concentrated at the leading edge and thus enable 
unidirectional migration towards increasing chemokine gradients. 
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   It has been well established that the arrest and firm adhesion of leukocytes to 
endothelial cells is also induced by chemokines (12,13).  Endothelial cell-bound 
chemokine signalling triggers the activation and subsequent increase in affinity of the 
β-integrins, LFA-1 and VLA-4 present on leukocytes (14,15).  These activated 
integrins then interact with cell adhesion molecules present on the endothelium, thus 
promoting leukocyte arrest and crawling (14).  Current evidence suggests that apical 
endothelial chemokines may also participate in the transendothelial migration of 
previously arrested leukocytes (16).   
1.3.1 Atypical Chemokine Receptors 
   Recently, an alternative group of chemokine receptors have emerged.  These 
‘atypical’ chemokine receptors (ACR) are heptaspanning membrane receptors and 
there are currently 5 family members: DARC, D6, CXCR7, CCRL1 and CCRL2.  
Although structurally homologous to classical chemokine receptors, they differ in that 
they are unable to signal along classical G-protein-mediated pathways normally 
activated upon chemokine binding (17).  This is due to the fact that they possess (or 
completely lack) a modified DRYLAIV motif within the second intracellular loop (17).  
This canonical motif is absolutely essential for coupling to G-proteins.  Nevertheless, 
ACRs can efficiently internalise chemokines (17,18) and, are thus perceived to play a 
role in the regulation of chemokine bioavailability (18) and in the generation of 
functional chemokine gradients (17).  ACRs may influence the response to chemokines 
both by scavenging chemokines and targeting them for lysosomal degradation or by 
transporting them across physiological barriers (17-19). 
1.4 CC-Chemokine Receptor 7 
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   The chemokine receptor, CCR7 is predominantly expressed by cells of the immune 
system including mature DCs, naïve T and B cells, central memory T cells (TCM) and 
regulatory T cells (TReg) (20).  The homeostatic chemokines, CCL19 and CCL21, are 
reported to be the sole ligands for CCR7.  Both chemokines appear to be constitutively 
expressed by fibroblastic reticular cells concentrated in the T cell areas of secondary 
lymphoid organs, such as the thymus, spleen and lymph nodes (20).  In particular, 
CCL19 is expressed on the lumen of HEVs, the principal route of entry into the lymph 
node for lymphocytes, and CCL21 by the afferent lymphatic endothelium (20).  Only 
in mice is CCL21 present on the luminal side of HEVs (20). 
1.4.1 Lymph Node Architecture 
   The lymph node is an encapsulated organ that is composed of two histologically 
distinct regions – the cortex and the medulla (Figure 1.1).  The cortex is further 
subdivided into the paracortex, which mainly consists of T cells, and the outer cortex, 
which is composed of primary B cell follicles and is the main site of germinal centre 
formation (21).  The medulla, on the other hand, comprises a dense network of 
medullary sinuses that are separated by medullary cords containing plasma cells, 
macrophages and T cells (21).  
   Lymph enters the lymph node via a series of afferent lymphatic vessels.  This lymph 
flows through to the subcapsular sinus and then drains to trabecular sinuses (21).  The 
lymph then filters through the LN and eventually collects in the medullary sinuses 
(21).  These medullary sinuses converge at the hilum to form the efferent lymphatic 
vessel, which carries lymph away from the lymph node (21). 
 18 
The Role of CCR7 in Lymph Node Homing and Positioning 
   In recent years, a number of lymphoid chemokine receptors (and corresponding 
ligands) have emerged that regulate the homing of leukocytes to lymph nodes.  
Immature DCs in the skin constantly patrol the tissue in search for antigen, which they 
process and present via MHC.  Upon exposure to inflammatory cytokines, the DCs 
undergo maturation and downregulate the expression of inflammatory chemokine 
receptors, whilst concomitantly upregulating CCR7 (22).  This upregulation is 
absolutely essential for the directed migration of DCs from the dermis toward CCL21-
expressing afferent lymphatics (15,22,23).  Similarly, entry of lymphocytes into the 
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Figure 1.1: The Structure of the Lymph Node 
 
The afferent lymphatic vessels carry lymph into the subcapsular sinus.  Macrophages sample 
the lymph for pathogens for presentation to B cells.  The lymph then drains into trabecular 
sinuses lined by fibroblastic reticular cells.  Chemokines are also transported in these sinuses 
to HEV to attract lymphocytes.  The lymph eventually collects in the medullary sinuses, which 
converge at the hilum, forming the efferent lymphatic vessel. 
Afferent Lymphatic vessel 
Efferent Lymphatic vessel 
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lymphatics is also dependent on CCR7 and its cognate ligands (20,23).  The number of 
T cells present in the LNs of CCR7-deficient mice is markedly reduced (20).  
Likewise, CCR7-deficient DCs display a strong reduction in their ability to enter 
dermal lymphatic vessels (23).   
CCR7 also plays a crucial role in the firm arrest and subsequent transmigration of 
leukocytes across the afferent lymph vessels (DCs) or HEVs (T cells) into the draining 
LN.  Using TNFα-activated Human Umbilical Vein Endothelial Cells (HUVEC) as an 
in vitro model of inflamed endothelium, Cinamon et al were able to demonstrate that 
adsorption of CXCL12 or CCL19 on the apical surface of HUVECs induced 
significant arrest of peripheral blood lymphocytes (PBL) (16).  In addition, 
approximately 70% of the arrested lymphocytes were able to successfully transmigrate 
across the endothelium (16).  Comparatively fewer lymphocytes could transmigrate in 
the absence of immobilised chemokines (16).  In DCs, neutralisation of CCL21 
effectively blocked transendothelial migration and was associated with a lack of β2 
integrin activation (15).   
   It is also widely accepted that CCR7 signals contribute to the proper positioning of 
immune cells and the generation of functional microenvironments within secondary 
lymphoid organs.  Naïve T cells constantly circulate through secondary lymphoid 
organs in search for DCs bearing their cognate antigen.  Activated DCs, under the 
influence of CCL19/21 expressed by HEV, traverse the subcapsular sinus and are 
guided into the deep paracortical T cell zone (TCZ) (23).  This process is of great 
importance as it increases the likelihood of naïve T cells encountering their cognate 
DC. Indeed, CCR7-deficient DCs fail to penetrate the TCZ and remain ‘trapped’ in the 
subcapsular sinus (23). Such defects in immune cell homing have been linked with 
impaired immunity and tolerance (20).  Signalling through CCR7 has also been 
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reported to control the positioning of follicular B cells at the T cell border, thus 
enabling T cell – B cell interactions (20). 
1.5 CCRL1: Chemocentryx Chemokine Receptor 
   CCRL1 (also known as CCX-CKR1, CCR10 and CCR11) is a relatively new 
member of the ACR superfamily and although studied to a lesser extent, is known to 
be the only ACR that binds with high affinity to homeostatic chemokines, namely 
CCL19, CCL21 and CCL25 (17).  As with all other ACRs, CCRL1 is incapable of 
initiating downstream signalling events that mediate physiological processes, such as 
chemotaxis and its exact function is largely unknown.  CCRL1 expression has been 
documented specifically in epidermal cells, thymic epithelial cells and stromal cells 
that line the LN marginal sinus (24).   
   The discovery that CCRL1 is able to bind the same ligands as CCR7 has led to the 
proposal that CCRL1 may function as a chemokine scavenger and may thus affect 
chemokine bioavailability and subsequent CCR7-mediated chemotactic responses (18).   
Stable transfection of HEK293 cells has demonstrated that upon chemokine exposure, 
both CCR7 and CCRL1 rapidly internalise CCL19. In CCRL1 expressing cells this 
also leads to very efficient lysosomal degradation (18).  Further internalisation of 
CCL19 through CCRL1 unlike CCR7, does not result in receptor desensitisation but 
rather leads to enhanced chemokine sequestration (18).  In support of this, mice 
lacking CCRL1 display significant increases in the levels of CCL19 and CCL21 within 
peripheral LNs and in the blood (19).   Despite the abundance of CCR7-ligands, 
CCRL1-deficient mice appear to have decreased lymph node cellularity (19) and 
display gross abnormalities in steady-state homing of CD11c+MHCIIhigh DCs (24).  
This may result from receptor desensitisation due to increased levels of CCL19 and 
CCL21 or may be due to the inability to establish pro-migratory chemokine gradients 
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(17,18).  CCRL1 has also been implicated in the differentiation of CD4+ T cells in vivo 
(19). 
1.6 The Role of CCR7 and its Atypical Chemokine 
Receptor in Lymph Node Metastasis 
   As previously mentioned, the regional draining LNs represent the most common site 
of metastasis for melanoma and the occurrence of such metastases is strongly 
correlated with poor patient outcome (8).  Interestingly, the invasion of lymphatic 
vessels by tumour cells and their subsequent migration to the SLN bears striking 
similarities with the normal trafficking of antigen-bearing DCs from the skin to 
secondary lymphoid organs during the course of inflammation.  Considering that the 
emigration of DCs to regional draining LNs is under the control of CCR7 and its 
ligands, it is likely that CCR7 may also be implicated in lymph node metastasis (Figure 
1.2).   
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   This is supported by clinical findings indicating that CCR7 is expressed by a number 
of tumour types including breast, cervix, head and neck, and melanoma (25-27).  
Furthermore, overexpression of CCR7 in B16 murine melanoma cells has been 
demonstrated to result in an approximate 700-fold increase in lymph node metastasis - 
an observation that is effectively blocked using a neutralising anti-CCL21 antibody 
(1,10). In accord with these findings, lymphatic endothelial cells express CCL21, 
which has been shown to stimulate the directed migration of malignant melanoma cells 
towards the lymphatics (11).  Recent data also indicates that CCR7 expression may be 
involved in lymphangiogenesis and anti-tumour immunity as the expression of the 
lymphatic marker, podoplanin, appears to be upregulated in CCR7-expressing B16 
 
  
 
 
 CCR7 
CCL21 
CCL21 
Figure 1.2: Melanoma Metastasis Resembles Immune Cell Homing to Lymph Nodes 
 
Activated DCs in the periphery undergo maturation and downregulate the expression of 
inflammatory cytokines, whilst concomitantly upregulating CCR7.  The upregulated expression 
of CCR7 enables DCs to respond chemotactically to CCL21 expressed by dermal lymphatic 
vessels.  The DCs then flow to the regional lymph node, which is rich in CCL21.  Likewise, 
melanoma tumour cells expressing CCR7 may invade afferent lymphatic vessels more efficiently 
and be retained in regional lymph nodes. 
Melanoma Tumour Cells Dendritic Cells 
Dermal Lymphatic Vessel 
Lymph Node 
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melanoma tumours, whilst the expression of interferon-γ-associated genes and MHC 
class I and II appear to be markedly reduced (28).   
 
   The role of CCR7 in cancer progression is clearly well established and there is now 
evidence to implicate CCRL1 in tumourigenesis and metastasis.  A significant 
correlation has been reported between CCRL1 expression and lymph node metastasis 
in human breast cancer, with lower levels of expression being associated with poorer 
prognosis (29). These results raise a number of questions and it will be interesting to 
see how CCRL1 expression affects the axis role of CCR7-CCL19/21 in nodal 
metastasis. 
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2. MATERIALS AND METHODS 
2.1 Materials 
Cell Lines 
• B16-F1 murine melanoma cell line obtained from ATCC (♯CRL-6323) 
• CCR7-transfected B16-F1 melanoma cell line obtained from Professor Sam T 
Hwang (1) 
Cell Culture 
• Dulbecco’s Modified Eagle Medium (DMEM) – Sigma-Aldrich, UK 
• RPMI 1640 (- L-Glutamine) – Sigma-Aldrich, UK 
Antibodies 
• Rat eFluor® 450 conjugated anti-mouse/human CD45R (B220) – eBioscience 
♯48-0452-82 
• FITC-conjugated anti-mouse CD45.2 – eBioscience ♯11-0454-85 
• Rabbit polyclonal antibody to TRP2 – Abcam ♯Ab74073 
• Polyclonal goat anti-rabbit IgG biotinylated – Dako ♯E0432 
• Rabbit polyclonal antibody to Lyve-1 – Abcam ♯Ab14917 
• Alexa Fluor® 555 donkey anti-rabbit IgG (H+L) – Invitrogen ♯A31572 
• Anti-mouse Lyve-1 eFluor® 660 – eBioscience ♯50-0443-82 
• Goat anti-mouse CCL21 – R&D Systems 
• CCXCKR (C-16) goat polyclonal IgG (CCRL1) – Santa Cruz Biotechnology ♯ 
SC-46835 
• Alexa Fluor® 647 donkey anti-goat IgG (H+L) – Invitrogen ♯A21447 
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• Alexa Fluor® 488 donkey anti-rat IgG (H+L) – Invitrogen ♯A11006 
• Langerin/CD207 monoclonal antibody – Dendtritics ♯DDX0362 
• Anti-mouse CCR7-PE conjugated IgG – eBioscience ♯12-1971-82 
• Anti-mouse CD16/32 purified IgG (Fc block) – eBioscience ♯14-0161-85 
• Purified rat anti-mouse CD31 – BD Pharmingen ♯550274 
• Anti-mouse CD11b eFluor® 450 – eBioscience ♯48-0112-82 
• Anti-mouse CD11c-FITC – eBioscience ♯11-0114-82 
• Anti-FITC/Oregon green rabbit IgG fraction Alexa Fluor® 488 conjugate – 
Invitrogen ♯A11090 
• Biotin conjugated anti-mouse CD3e – eBioscience ♯13-0033-85 
• Rat anti-mouse CD4-647 – eBioscience ♯14-0043-81.  Conjugated in-house by 
Dr. David Withers. 
• eFluor® 660 conjugated anti-mouse CD8 (alpha subunit, CD8a, Ly-2) – 
eBioscience ♯50-0087-82 
• Anti-mouse/rat Foxp3-FITC – eBioscience ♯50-0087-82 
• Goat anti-rat FITC – Southern Biotech ♯3030-02 
• Goat anti-rabbit FITC – Southern Biotech ♯4050-02 
• Alexa Fluor® 488 donkey anti-rat IgG (H+L) – Invitrogen ♯A21208 
Primers 
• 11com5 primer – obtained from Professor Robert Nibbs (19) 
• 3IRES primer – obtained from Professor Robert Nibbs (19) 
• 11wt5 primer – obtained from Professor Robert Nibbs (19) 
Buffers and Solutions 
• Endogenous blocking solution: 10% serum + 1% BSA PBS 
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• Triton X blocking solution: 0.3% triton X + 1% BSA PBS 
• Biotin block solution: 0.0033% biotin + PBS 
• Avidin block solution: 0.033% avidin + PBS 
• Tween-20 blocking solution: 0.5% tween-20 + 1% BSA PBS 
• FACS buffer: DPBS, 2% FCS, 1mH EDTA, 0.06% sodium azide 
• RPMI + 2% FCS 
• 1.5% agarose gel: 1.5g agarose + 100ml 5x TBE buffer + 20µl SYBR® safe 
DNA gel stain 
• PCR lysis buffer: 25mM sodium hydroxide, 0.2mM EDTA 
• PCR neutralising buffer: 40mM Tris-HCL (pH≈5), DNAse-free water 
Additional Materials 
• Streptavidin-Alexa Fluor® 555 conjugate – Invitrogen ♯S32355 
• Penicillin-Streptomycin – Gibco ♯15070-063 
• 10% Fetal Bovine Serum – Gibco ♯10437-028 
• TripLE™ Express (+phenol red) – Gibco ♯12605-028 
• Paraformaldehyde (PFA) – Sigma-Aldrich ♯158127 
• Microscope cover slips – Menzel-Gläser ♯BB024032A1 
• Dulbecco’s Phosphate Buffered Saline (DPBS) – Sigma ♯D8662 
• Dulbecco’s Phosphate Buffered Saline (DPBS) (-calcium/magnesium) – Sigma 
♯D8537 
• Phosphate Buffered Saline (PBS) tablets – Sigma-Aldrich ♯P4417-100TAB 
• Triton X-100 – VWR International 
• Tween-20 – Fischer Scientific 
• Prolong® gold anti-fade reagent – Invitrogen ♯P36930 
 27 
• Agarose, for routing use – Sigma-Aldrich ♯A9539-500G 
• Probumin® bovine serum albumin powder (BSA) – Millipore ♯82-045-1 
• Biotin powder – Sigma-Aldrich ♯B4639 
• Streptavidin – Sigma-Aldrich ♯S4762 
• Methanol, laboratory reagent grade – Fischer Scientific ♯M/3950/17 
• DAPI – Invitrogen ♯D1306 
• Goat serum – Sigma-Aldrich ♯G9023-10ml 
• Donkey Serum – Sigma-Aldrich ♯D9663-10ml 
• Multispot microscope slides – Henley Essex ♯PH-005 
• 70µm cell strainer – BD Falcon™ ♯352350 
• Deoxyribonucleotide triphosphate (dNTP) mix – Bioline ♯BIO-39053 
• NH4 PCR reaction buffer – Bioline ♯BIO-37025 
• MgCl2 solution – Bioline ♯BIO-37026 
• RNAse-free water – Qiagen ♯129112 
• Biotaq® DNA polymerase – Bioline ♯BIO-21041 
• 100bp DNA ladder – New England Biolabs ♯N3231S 
• SYBR safe DNA gel stain – Invitrogen ♯533102 
• Acetone – Sigma-Aldrich ♯179124 
• Trypsin/Ethylenediaminetetraacetic acid (EDTA) – Invitrogen #15400-054 
• Ultrapure 10x TBE buffer – Gibco ♯15581-044 
• Collagenase D – Roche ♯11088858001 
• DNAse – Roche ♯112649322001 
• Near infrared cell death stain – Invitrogen ♯L10119 
• Aqua fluorescent reactive dye – Invitrogen ♯L34960 
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• Firefly D-Luciferin, potassium salt – Caliper Life Sciences ♯119222 
• Puromycin (10µg/ml) – Sigma ♯P9620 
• Geneticin (50μg/ml) – Gibco ♯10131-019  
Murine Lymph Node Tissue Sections 
Tissue section Additional Information 
4/12 Inguinal Lymph Node Wild-type 
Non-tumour bearing 
3/12 Inguinal Lymph Node CCRL1-knockout 
Non-tumour bearing 
275/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
276/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
272/11 Inguinal Lymph Node CCRL1-knockout 
CCR7+ tumour bearing 
274/11 Inguinal Lymph Node CCRL1-knockout 
CCR7+ tumour bearing 
273/11 Inguinal Lymph Node CCRL1-knockout 
CCR7+ tumour bearing 
278/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
279/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
280/11 Inguinal Lymph Node CCRL1-knockout 
CCR7+ tumour bearing 
257/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
258/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
259/11 Inguinal Lymph Node Wild-type 
CCR7+ tumour bearing 
25/12 Inguinal Lymph Node CCRL1-knockout 
Non-tumour bearing 
26/12 Inguinal Lymph Node Wild-type 
Non-tumour bearing 
9/12 Inguinal Lymph Node CCRL1-knockout 
Non-tumour bearing 
10/12 Inguinal Lymph Node Wild-type 
Non-tumour bearing 
141/11 Inguinal Lymph Node CCRL1-knockout 
C57BL/6 non-CCR7 tumour bearing 
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2.2 Methods 
2.2.1 Mouse Strains 
   C57BL/6 mice and CCRL1-/- mice were obtained from Dr. Robert Nibbs (19).  Mice 
were housed at the Biomedical Services Unit (University of Birmingham, UK) in 
accordance with institutional and National Institutes of Health guidelines.   
2.2.1.1 PCR Genotyping 
   The knockout-mice generated and used in these experiments were of a heterozygous 
breed.  It was therefore necessary to characterize the mice to determine their genotype.  
The genotypes were identified by PCR of genomic DNA prepared from ear-punch 
tissue.  The tissue was firstly lysed with 75μl of PCR lysis buffer at 95°C for 20 
minutes.  The lysis buffer was then inactivated upon addition of 75μl of PCR 
neutralising buffer and the samples vortexed briefly.  A 2μl aliquot was taken and 
added to 10μl of PCR reaction master mix.  The primer sets used are listed in 
Appendix A: Table 1.  The samples were then centrifuged for 30 seconds at 1000rpm 
before being PCR amplified.  The 1.5% agarose gels were prepared on the day of use 
and were loaded with 10μl of sample DNA and 10μl of 100bp DNA ladder.  They 
were then run at +80V for approximately 30 minutes and then analysed using SYBR 
safe DNA gel stain.  
2.2.2 Characterisation of B16-CCR7 Melanoma Cell Line 
2.2.2.1 Cell Culture 
   The highly metastatic B16-F1 and CCR7-transfected B16-F1 (B16-CCR7) 
melanoma cell lines were routinely cultured in DMEM media supplemented with 10% 
FBS, penicillin-streptomycin and L-glutamine.  Cell cultures were incubated at 37°C in 
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a humidified atmosphere containing 5% CO2 in air until confluent.  Cells were 
detached using 2ml of TripLE™ Express for 2-3 minutes at 37°C and harvested in 8ml 
of complete media.  The cell suspension was then centrifuged for 4 minutes at 250g 
(1076rpm) and the supernatant aspirated.  For cell culture maintenance, the cell pellet 
was resuspended in 10ml of complete media and a 1:12 dilution carried out.  The 
appropriate volume of cell suspension was then transferred to a vented 75cm3 tissue 
culture flask containing pre-warmed media.  The B16-CCR7 cell line was selected for 
both CCR7 and luciferase expression by addition of geneticin (1000μg/ml) and 
puromycin (2μg/ml).  
2.2.2.2 Flow Cytometry 
   For Flow Cytometry, cells were scraped off the 75cm3 tissue culture flask into 1ml of 
cold PBS using a cell scraper.  The cells were then centrifuged at 300g for 4 minutes 
and the supernatant discarded.  The cell pellets were resuspended in 500μl RPMI 2% 
FCS containing collagenase D (1:50) and DNAse (1:200) and incubated at 37°C for 10 
minutes with gentle shaking.  After 10 minutes, 5μl of EDTA was added and the cell 
suspensions were left on ice for 5 minutes before being passed through a 70μm cell 
strainer, followed by 5ml of FACS buffer.  The cells were then counted and seeded at 
0.5x106 cells/well in to a clear, round-bottom 96-well plate.  Prior to staining, the cells 
were incubated on ice for 10 minutes with anti-CD16/32 antibody to block the Fc 
receptors.  A PE-conjugated anti-CCR7 antibody and a near infrared cell death stain 
were used to stain the cell suspensions and to gate out non-viable cells.  
Immunostained cells were then analysed using the Beckman Coulter CyAn™ ADP 
analyser and FlowJo software. 
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2.2.3 Evaluation of B16-CCR7 Melanoma Cell Line 
2.2.3.1 Seeding Cells For Intravital Imaging 
   B16-F1, parental B16-CCR7 (non-selected) and puromycin-/geneticin-selected B16-
CCR7 cells were seeded into a black-walled 96-well tissue culture plate at a 1:2 
titration with a starting concentration of 1x105 cells/ml.  The cells were incubated 
overnight at 37°C to allow them to adhere.  Prior to imaging, the media was aspirated 
and replaced with 100μl/well of D-luciferin diluted in complete media.  The plates 
were imaged using the IVIS® Spectrum intravital microscope (Caliper Life Sciences) 
and analysed using the IVIS® Living Image software (Caliper Life Sciences).  Region-
of-interest (ROI) measurements were exported to Microsoft Excel.  Graphs were 
generated in Microsoft Excel by plotting the ROI values for each experimental 
condition. 
2.2.3.2 Inoculation of Mice With B16-CCR7 Melanoma Cells 
    B16-F1 and puromycin-/geneticin-selected B16-CCR7 cells were harvested by 
trypsinisation and washed in cold PBS.  The cells were then counted and resuspended 
at 60x106 cells/ml in the appropriate volume of cold PBS.  The cells were filtered 
through a 70μm cell strainer and the volume readjusted, if necessary, to reach a final 
concentration of 50x106 cells/ml.  For ear injections, 20μl of cell suspension was 
injected into the subcutaneous space under the central dorsal surface of the ears of both 
wildtype (WT) and CCRL1-/- C57BL/6 mice.  Mice were sacrificed after 3 weeks of 
growth.  
2.2.3.3 Intravital Microscopy 
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   Prior to anaesthetisation, mice were weighed and received D-Luciferin via i.p. 
injection (10μl per kg body weight).  After 5 minutes, the mice were anaesthetised with 
2.5% isoflurane and prepared for intravital imaging by shaving the area surrounding 
the ears.   The mice were imaged using the IVIS® Spectrum intravital microscope 
(Caliper Life Sciences) and the images analysed using IVIS® Living Image software 
(Caliper Life Sciences).  The tumour diameter and radius was also measured using a 
caliper.  ROI measurements were exported to Microsoft Excel and graphs generated by 
plotting the ROI values for each mouse versus the tumour diameter or tumour radius. 
2.2.4 Immunofluorescence 
2.2.4.1 Immunofluorescent Detection of Tumour Cells 
   Serial lymph node sections with a thickness of 6μm were cut using a cryostat, 
mounted on to slides and air-dried for 30 minutes before being stored at -80°C.  Before 
use, sections were fixed in methanol on ice for 10 minutes, air-dried for 30 minutes 
and then hydrated in PBS.  Prior to staining, sections were treated separately with 
avidin (1:30) and biotin (1:6) for 15 minutes at room temperature to prevent any non-
specific staining.  In order to block endogenous Fc receptors, sections were also 
incubated for 15 minutes at room temperature with an endogenous blocking solution 
containing 10% normal serum derived from the host species of the secondary antibody.  
All antibodies were diluted in this endogenous blocking solution.   
   Rabbit anti-mouse TRP-2 antibody (1:1000) was applied to the sections for 40 
minutes at room temperature.  Sections were then washed for 10 minutes with PBS and 
incubated with goat anti-rabbit biotinylated antibody (1:500).  After a 30 minute 
incubation at room temperature the sections were washed in PBS and Streptavidin-
Alexa Fluor® 555 conjugate (1:500), rat anti-mouse CD45R (B220) eFluor® 450 
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(1:25), rat anti-mouse Lyve-1 eFluor® 660 (1:50) and mouse anti-mouse CD45.2-FITC 
conjugated antibody (1:50) applied to the sections for 30 minutes at room temperature 
shielded from light.  Negative control sections were treated under equivalent 
conditions with no primary antibodies and were counterstained with DAPI.  Slides 
were mounted with Prolong Gold mounting media and were visualised using a Zeiss 
LSM 510 Meta confocal microscope.  Images were analysed using the Zeiss LSM 
Image Browser software and then exported to Microsoft Powerpoint. 
   Several different methods for staining tumour cells in the lymph node were tested, 
however, all results described were generated using the staining protocol outlined 
above.  Previously tested methods included fixing lymph node sections in acetone at 
4°C for 20 minutes followed by direct staining of tumour cells with streptavidin-Alexa 
Fluor® 488, however this method resulted in non-specific staining of adipose tissue 
surrounding the lymph node.  Lymph node sections were also stained using an anti-
mouse Melanoma (HMB45 + DT101 + BC199) antibody followed by the Vector® 
Mouse On Mouse (MOM) Immunodetection kit (Vector Laboratories), however there 
was significant non-specific staining of the B cell areas. 
2.2.4.2 Immunofluorescent Detection of CCL21 
   Serial lymph node sections were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature, washed in PBS for 10 minutes and endogenous Fc receptors 
blocked with endogenous blocking solution.  For the detection of extracellular CCL21, 
goat anti-mouse CCL21 (1:15), rat anti-mouse PNad (1:50) and rabbit anti-mouse 
Lyve-1 (1:100) were diluted in endogenous blocking solution and applied directly to 
the sections for 45 minutes at room temperature.  After a 10 minute PBS wash step, the 
sections were incubated with Alexa Fluor® 488 donkey anti-rat antibody (1:300), Alexa 
Fluor® 647 donkey anti-goat antibody (1:100) and Alexa Fluor® 555 donkey anti-rabbit 
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antibody (1:500) diluted in endogenous blocking solution for 30 minutes at room 
temperature shielded from light.  Following this, the sections were washed in PBS for 
10 minutes, counterstained with DAPI and mounted. 
   For intracellular detection of CCL21, sections were permeabilised using 0.3% triton 
X-100 for 15 minutes at room temperature prior to incubation with the primary 
antibodies.  All antibodies used were diluted in 0.3% triton X-100. 
2.2.4.3 Immunofluorescent Detection of CCRL1 
   Sections were fixed in acetone at 4°C for 20 minutes, air-dried for 30 minutes and 
blocked with endogenous blocking solution.  Goat anti-mouse CCRL1 (1:50) and 
hamster anti-mouse CD11c-FITC conjugated antibody (1:50) were prepared in tween-
20 and then applied to the sections for 45 minutes at room temperature.  After a 10 
minute PBS wash step, the sections were incubated with Alexa Fluor® 555 donkey 
anti-rabbit antibody (1:500), rabbit anti-FITC 488 conjugated antibody (1:200) and rat 
anti-mouse Lyve-1 eFluor® 660 (1:50) for 30 minutes at room temperature shielded 
from light.  Sections were then washed in PBS for 10 minutes, counterstained with 
DAPI and mounted. 
2.2.5 Data Analysis 
Images were exported to and analysed using the LSM 510 software package.  Raw data 
was exported to excel and graphs generated by plotting ROI values for each 
experimental condition against cell number or tumour size. 
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3. AIMS AND OBJECTIVES 
The main objective was to investigate CCR7-driven metastasis and survival in the 
lymph node and whether host CCRL1 expression in the lymph node affects these 
processes.  Further research included the inoculation of B16-F1 cells transduced with 
CCR7 and luciferase in the ear skin of WT and CCRL1-KO mice to evaluate the 
kinetics of tumour growth at the inoculation site and within tumour-draining lymph 
nodes. 
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4. RESULTS 
4.1. Immunofluorescent Detection of Tumour Cells in the 
Lymph Node 
4.1.1. Development of an Experimental Protocol That Allows the Early 
Detection of B16 Melanoma in the Lymph Node 
   The identification of metastatic melanoma in the sentinel LN has traditionally 
involved haematoxylin and eosin (H&E) staining of LN sections.  Although it is 
possible to detect, with ease, larger metastatic foci in H&E-stained sections, smaller 
metastatic clusters and sparse isolated cells associated with early metastasis may be 
missed.  HMB-45, a monoclonal antibody directed against melanoma antigen, 
represents another widely used immunohistochemical staining technique that is 
regarded by some to be a useful tool in the detection of human primary and early 
metastatic melanoma (30).  The antibody has been known to react with melanoma 
cells, junctional nevus cells and foetal melanocytes but not with other non-melanoma 
malignancies, thus demonstrating sound specificity (30).  Although the antibody is 
known to cross-react with mouse melanoma, the sensitivity of the antibody for 
melanoma cells has come into question and it may not provide a reliable means for the 
detection of single isolated tumour cells (30).  It was therefore, necessary to develop a 
more precise and reliable method of staining melanoma cells in early murine LN 
metastasis.  
   Previous work within the group had suggested that B16 melanoma cells bind to 
streptavidin with high affinity.  In order to investigate whether streptavidin staining 
would be suitable for the detection of B16 melanoma cells in the LN, murine WT and 
CCRL1-KO inguinal LN sections, both tumour bearing and non-tumour bearing, were 
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stained with a streptavidin-fluorophore conjugate. Streptavidin-positive cells were 
found to be closely associated with the subcapsular sinus but were also found to be 
present in non-tumour bearing sections, thus demonstrating non-specific binding 
(Figure 4.1). 
   Staining was next attempted using a murine monoclonal antibody raised against 
melanoma antigens (HMB-45, DT101, BC199).  In an attempt to minimise any 
background staining, the Vector® MOM immunodetection kit was employed and used 
according to the manufacturer’s guidelines, however, non-specific staining was noted 
in non-tumour draining mesenteric LNs (Figure 4.2).  Staining persisted in sections 
that were not treated with the primary antibody. 
   Mesenteric LN sections were also stained using a rabbit polyclonal anti-TRP-2 
primary antibody after blocking endogenous biotins.  TRP-2 is an enzyme involved in 
melanin biosynthesis and is highly expressed by melanocytes (31,32).  TRP-2-positive 
staining was identified in all melanoma tumour sections, with relatively low 
background staining in mesenteric LNs (Figure 4.3). 
4.1.2. Optimisation of B16 Melanoma Staining in the Lymph Node 
   WT inguinal LN sections were stained for both TRP-2 and the hematopoietic specific 
marker CD45 to better differentiate the B16 melanoma cells from the hematopoietic 
cells within the lymph node.  Sections were also counterstained with the nuclear dye, 
DAPI, to confirm the presence of tumour cells based upon differences in cell nuclear 
morphology.  Large tumour foci were clearly visible upon inspection of both DAPI 
(data not shown) and TRP-2 staining (Figure 4.4).  Furthermore, these foci were 
largely devoid of CD45 staining with the exception of a few scattered, CD45high TRP-
2- cells.  Many of the LNs also displayed isolated, scattered TRP-2+ cells in close 
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proximity with the subcapsular sinus, of which some were identified as being positive 
for CD45 also.   
 
4.1.3. The effect of host CCRL1 expression on metastatic establishment 
and distribution of CCR7-expressing B16-F1 (B16-CCR7) 
melanoma in the lymph node 
    Having established the optimal staining conditions, it was possible to investigate 
where B16-CCR7 melanoma establishes in the lymph node and whether CCRL1 
expression could influence melanoma establishment and distribution.  WT and 
CCRL1-KO tumour bearing LNs were stained according to the protocol described in 
section 2.2.4.1.  Histological analysis of LN sections indicated that CCR7-expressing 
B16 melanoma preferentially establishes within the B cell areas and also surrounding 
the efferent lymphatic vessels of the LN (Figure 4.5a and b).  CCRL1 expression did 
not appear to alter the growth or distribution of B16-CCR7 melanoma within the LN.  
Eight of eight WT LNs and four of six CCRL1-KO LNs showed tumour foci in the B 
cell area (Figure 4.5c).  Anti-TRP-2 staining was negative in the fifth CCRL1-KO LN 
(data not shown) and the sixth CCRL1-KO LN displayed scattered B16-CCR7 
melanoma cells throughout the cortex and medulla (Figure 4.5a and b).  Once again, 
brightly stained CD45high TRP-2- cells were found to be dispersed within the foci 
(Figured 4.5b). 
4.1.4. Characterisation of the Metastatic B16-CCR7 Melanoma Tumour 
Microenvironment 
  In an attempt to further characterise the CD45high TRP-2- cells present within the 
tumour foci, serial inguinal LN sections were stained with a panel of common immune 
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cell markers.  Relatively few CD3+ cells were present within metastatic foci (Figure 
4.6).  Conversely, large proportions of CD4+ cells were present, both within and 
surrounding the foci.  However, the relatively few CD3+ cells within the foci suggests 
that these cells may not necessarily represent T cells.  There were also no FOXP3+ 
regulatory T cells present within the infiltrating T cells of the foci.  A large number of 
CD8+ cells were, however, detected in the LN sections, mostly surrounding the foci.  
Relatively little CD11c or CD11b staining was detected.  No noticeable differences in 
staining were observed in WT and CCRL1-KO LNs for any of the immune cell 
markers tested (Figure 4.6 a and b).   
 
4.2. The Effect of Host CCRL1 Expression on CCL21   
Protein Levels and Distribution in the Lymph Nodes of 
Tumour Bearing and Non-Tumour Bearing Mice 
4.2.1. CCL21 Expression in PFA-Fixed Lymph Node Sections 
Permeabilised with Triton-X 
   Next we sought to address whether CCL21 expression is altered in tumour bearing 
LNs in the presence or absence of CCRL1 expression.  Inguinal LN sections were 
permeabilised with triton-X and stained for CCL21 according to the protocol outlined 
in section 3.2.4.2.  CCL21 expression appeared to be downregulated in the subcapsular 
sinus of both tumour bearing WT and CCRL1-KO LNs when compared with non-
tumour bearing WT LNs (Figure 4.7). Of note, Langerin cells accumulated within the 
subcapsular sinus of CCRL1-KO LNs, which is in concordance with unpublished data 
from the group.  
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4.2.2. CCL21 Expression in PFA-Fixed Non-Permeabilised Lymph 
Node Sections 
   CCL21 expression was also assessed in non-permeabilised LN sections.  Again, 
expression appeared to be downregulated in the sinus of tumour bearing WT and 
CCRL1-KO LN sections when compared to non-tumour bearing WT and CCRL1-KO 
LN sections, thus suggesting that LNs bearing micrometastases may inhibit CCL21 
expression (Figure 4.8a).  Interestingly, presence of CCL21 in the tumour was also 
observed (Figure 4.8b).  
4.3. CCRL1 Expression in the Lymph Nodes of Tumour 
Bearing and Non-Tumour Bearing Mice 
   LN sections were then stained for CCRL1 according to the protocol described in 
section 2.2.4.3 to ascertain whether expression is altered in tumour bearing LNs.  
Similarly, CCRL1 expression appeared to be reduced in the sinus of WT tumour 
bearing LNs when compared with WT non-tumour bearing LNs (Figure 4.9), 
suggesting that LNs bearing micrometastases may also suppress the expression of 
CCRL1. 
 
4.4. Establishment of CCR7-Expressing B16-F1 (B16-
CCR7) Melanoma in Wild-Type and CCRL1-Knockout 
Mice 
   As the majority of the LNs displayed large, well-defined metastases it was not 
possible to examine the kinetics of B16 melanoma tumour growth and to assess the 
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effect of CCRL1 on the CCR7-CCL19/21 chemokine axis in early LN metastasis in 
vivo.  In order to address this, B16 melanoma cells transduced with CCR7 and 
luciferase (B16-CCR7) were utilised.  Previous work in the group has demonstrated 
that the cells express CCR7 to a significantly higher level than control B16-F1 cells 
(unpublished data).  The levels of other chemokines and their receptors were also 
measured and it was revealed that the cells were negative for the expression of 
CXCR4, CXCR5, CCR9, CCL19, CCL21, CXCL13 and CXCL12 (unpublished data).  
   In this small tumour experiment, the cells were exposed to antibiotic selection to 
enhance tumour cell expression of luciferase and to eliminate CCR7- melanoma cells.  
These cells were then injected in to the ears of both WT and CCRL1-KO C57BL/6 
mice and early tumour cell behaviour monitored by luciferase activity using the IVIS 
Spectrum® intravital microscope.   
 
4.4.1. PCR Genotyping 
    Initial experiments involved determining the genotype of the mice so that WT and 
CCRL1-homozygous KO mice could be identified and selected for inoculation.  The 
genotype was determined by PCR using two forward primers, each one distinct for the 
KO or WT allele, and a common reverse primer.  The WT allele was present at 610bp 
and the KO allele at 420bp.  Of the 23 mice genotyped, 5 were revealed to be WT, 7 
were homozygous KOs and 11 were of a heterozygous nature (Figure 4.10).  Mice 
taken forward for inoculation are marked with an asterisk (Figure 4.10b). 
 
4.4.2. Optimisation of the Expression of Luciferase and CCR7 in the 
B16-CCR7 cell line 
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   Luciferase activity in B16-CCR7 cells was assessed using the IVIS Spectrum® 
intravital microscope and converted into luciferase expression based on cell counts.  
B16-F1 cells transduced with luciferase were shown to have the highest level of 
luciferase activity (Figure 4.11a – before selection).  The B16-CCR7 cells showed 
much weaker activity and, as a result, may not have provided enough sensitivity to 
accurately follow and measure tumour development from a small number of B16 
melanoma cells.  In an effort to increase the sensitivity of the B16-CCR7 cell line, the 
cells were exposed to the antibiotic, puromycin to select for high luciferase-expressing 
cells.  Parental B16-CCR7 cells were not selected with puromycin.  Unfortunately, 
selection did not result in enhanced luciferase activity (Figure 4.11a – after selection). 
   B16-CCR7 cells were also exposed to the antibiotic, geneticin, in order to select for 
CCR7 expression.  Once again, parental B16-CCR7 cells were not selected with 
geneticin.  Although, antibiotic selection did not eliminate the population of CCR7low 
cells, it did result in a shift in CCR7 expression in CCR7+ cells towards much higher 
levels (Figure 4.11b). 
 
4.4.3. Ear Injection of B16-CCR7 Cells in Wild-Type and CCRL1-
Knockout Mice 
   Following optimisation, B16-CCR7 cells were injected in to the ears of 4 WT and 3 
CCRL1-KO C57BL/6 mice to compare metastasis kinetics between the groups.  After 
7 days, the mice were examined for the accumulation of B16-CCR7 cells in the ear.  
All CCRL1-KO mice displayed established tumours at the site of injection (not 
shown).  Interestingly, none of the WT mice had visible tumours at this stage, 
suggesting that CCRL1 may play a protective role in the early stages of primary 
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tumour formation.  After an additional 11 days, the mice were examined again.  Only 
1 of the 4 WT mice had a visible tumour at the site of injection (not shown).  
   To evaluate the sensitivity of the B16-CCR7 cell line, the CCRL1-KO mice were 
imaged using the IVIS Spectrum® intravital microscope, 18 days post-inoculation.  
Primary tumours were detected but no LN metastases were visible (Figure 4.12a).  
The overall size of each primary tumour was also measured and was shown to bear no 
correlation with luciferase expression, with the smallest tumour (mouse #0) appearing 
to have the greatest level of luciferase activity (Figure 4.11b).  For this reason, the cell 
line would not be suitable for the non-invasive detection and quantification of tumour 
cells in vivo. 
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Lyve-1    CD4    Streptavidin 
Figure 4.1: Direct Immunofluorescent Staining of Lymph Node Sections Using a 
Streptavidin-Fluorophore Conjugate. 
 
Representative images of inguinal lymph node sections from WT and CCRL1-KO C57BL/6 
mice.  CCRL1-KO mice received 1x105 CCR7-expressing B16-F1 melanoma cells via 
subcutaneous injection.  Mice were sacrificed after 3 weeks and serial lymph node sections cut 
and frozen.  Frozen sections were acetone-fixed for 20 minutes at 4°C and then stained for the 
presence of CD4+ T cells (blue), LYVE-1+ lymphatic vessels (red) and streptavidin binding 
B16-F1 melanoma cells (green).  Sections were then counterstained with DAPI and mounted 
using ProLong Gold.  Images were taken at 10x (WT) and 25x (KO) magnification using the 
Zeiss LSM 510 confocal microscope.  N=3 per group. 
3/12 
WT 
 Non-Tumour Bearing 
272/11 
KO 
Tumour Bearing 
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Figure 4.2: Indirect Immunofluorescent Staining of Lymph Node and Melanoma 
Tumour Sections Using an Anti-Melanoma Primary Antibody. 
 
Representative images of mesenteric lymph node or melanoma tumour sections taken from 
WT C57BL/6 mice.  Frozen sections were acetone-fixed for 20 minutes at 4°C and then 
stained using a melanoma antigen-specific (HMB45, DT101, BC199) primary antibody (green) 
at a concentration of 5x106 mg/ml followed by the Vector® Mouse On Mouse (MOM) 
Immunodetection kit (Vector Laboratories).  Sections were mounted using ProLong Gold and 
analysed at 10x magnification using the Leica DM6000 research microscope.  N=1 per group. 
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Melanoma Tumour Mesenteric LN 
Tyrosine Related Protein-2 
Figure 4.3: Indirect Immunofluorescent Staining of Lymph Node and Melanoma 
Tumour Sections Using an Anti-TRP2 Primary Antibody. 
 
Mesenteric lymph node and melanoma tumour sections taken from WT C57BL/6 mice were 
methanol-fixed for 10 minutes at 4°C and stained with an anti-tyrosine related protein-2 (TRP-
2) primary antibody at a concentration of 1µg/ml.  Sections were then mounted using ProLong 
Gold and analysed at 25x magnification using the Zeiss LSM 510 confocal microscope. N=2 
per group. 
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Figure 4.4: Immunofluorescent Staining for TRP-2 and CD45 Enables the Accurate 
Identification of CCR7-expressing B16-F1 (B16-CCR7) Melanoma Cells in the Lymph 
Node. 
 
Representative images of inguinal lymph node sections taken from WT C57BL/6 mice.  Mice 
received 1x105 CCR7-expressing B16-F1melanoma cells via subcutaneous injection.  Mice 
were sacrificed after 3 weeks and serial lymph node sections cut and frozen.  Frozen sections 
were methanol-fixed for 10 minutes at 4°C and stained for the presence of B16-CCR7 
melanoma cells (red) using the anti-TRP-2 primary antibody at a concentration of 1µg/ml, 
LYVE-1+ lymphatic vessels (blue) and CD45+ immune cells (green).  Sections were then 
counterstained with DAPI and mounted using ProLong Gold.  Images were taken at 25x 
magnification using the Zeiss LSM 510 confocal microscope.  N=1 per group. 
 
TRP-2    Lyve-1    CD45 
WT 
Tumour Bearing 
275/11 
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a) 
 
TRP-2    Lyve-1    CD45    B220 
Figure 4.5a: Metastatic B16-CCR7 Melanoma Establishes Within the B Cell Areas of the Lymph 
Node. 
 
a) Representative images of inguinal lymph node sections taken from WT and CCRL1-KO C57BL/6 
mice.  Mice received 1x105 CCR7-expressing B16-F1 melanoma cells via subcutaneous injection.  
Mice were sacrificed after 3 weeks and serial lymph node sections cut and frozen.  Frozen sections were 
methanol-fixed for 10 minutes at 4°C and stained for the presence of B16-CCR7 melanoma cells (red) 
using the anti-TRP-2 primary antibody at a concentration of 1x10-3 mg/ml, LYVE-1+ lymphatic vessels 
(blue), CD45+ immune cells (green) and B220+ B cells (grey) (sections 259/11, 275/11 and 274/11 
only).  Sections were then mounted using ProLong Gold.  Images were taken at 10x magnification 
using the Zeiss LSM 510 confocal microscope and merged together using Abode® Photoshop to create 
larger lymph node scans.  N=3 per group. 
 
WT 
Tumour Bearing 
KO 
Tumour Bearing 
275/11 276/11 
273/11 274/11 
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Figure 4.5b/c: Metastatic B16-CCR7 Melanoma Establishes Within the B Cell Areas of the Lymph 
Node. 
 
b) Representative images of inguinal lymph node sections taken from WT and CCRL1-KO C57BL/6 
mice.  Mice received 1x105 CCR7-expressing B16-F1 melanoma cells via subcutaneous injection.  Mice 
were sacrificed after 3 weeks and serial lymph node sections cut and frozen.  Frozen sections were 
methanol-fixed for 10 minutes at 4°C and stained for the presence of B16-CCR7 melanoma cells (red) 
using the anti-TRP-2 primary antibody at a concentration of 1x10-3 mg/ml, LYVE-1+ lymphatic vessels 
(blue), CD45+ immune cells (green) and B220+ B cells (grey).  Sections were then mounted using 
ProLong Gold.  Images were taken at 10x, 25x and 40x magnification using the Zeiss LSM 510 confocal 
microscope.  N= 8 per group for WT LNs.  N=6 per group for CCRL1-KO LNs.  c) Table showing the 
number of tumour bearing WT and CCRL1-KO lymph node sections displaying metastatic foci within the 
B cell zone. 
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Figure 4.6: Immunofluorescent Staining of Tumour Bearing Lymph Node Sections for 
Common Immune Cell Markers. 
 
a) Representative images of inguinal lymph node sections taken from WT C57BL/6 mice. b) 
Representative images of inguinal lymph node sections taken from CCRL1-KO C57BL/6 
mice.  Mice received 1x105 CCR7-expressing B16-F1 melanoma cells via subcutaneous 
injection.  Mice were sacrificed after 3 weeks and serial lymph node sections cut and frozen.  
Frozen sections were methanol-fixed for 10 minutes at 4°C and stained for various immune 
cell markers.  Sections were then mounted using ProLong Gold.  Images were taken at 40x 
magnification using the Zeiss LSM 510 confocal microscope.  N=1 per group.  
 
a) 
b) 
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Figure 4.7: CCL21 Expression Appears to be Reduced in the Sinus of Permeabilised CCRL1-
Knockout Lymph Node Sections. 
 
Representative images of inguinal lymph node sections taken from WT and CCRL1-KO C57BL/6 mice.  
Mice received 1x105 CCR7-expressing B16-F1 melanoma cells via subcutaneous injection.  Mice were 
sacrificed after 3 weeks and serial lymph node sections cut and frozen.  Frozen sections were fixed in 4% 
PFA for 10 minutes and permeabilised in 0.3% Triton-X100 before being stained for the presence of LYVE-
1+ lymphatic vessels (red), Langerin cells (green) and CCL21 (blue).  Sections were then counterstained 
with DAPI and mounted using ProLong Gold.  All images were taken at 25x magnification using the Zeiss 
LSM 510 confocal microscope.  N=2 per group for tumour bearing LNs.  N=1 for non-tumour bearing LNs. 
 
276/11 273/11 
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Figure 4.8: CCL21 Expression Appears to be Reduced in the Sinus of Non-Permeabilised CCRL1-
Knockout Lymph Node Sections. 
 
a) Representative images of inguinal lymph node sections taken from WT and CCRL1-KO C57BL/6 mice 
at 25x magnification. b) Representative images of inguinal lymph node sections taken from WT and 
CCRL1-KO C57BL/6 mice at 10x magnification.  Mice received 1x105 CCR7-expressing B16-F1 
melanoma cells via subcutaneous injection.  Mice were sacrificed after 3 weeks and serial lymph node 
sections cut and frozen.  Frozen sections were fixed in 4% PFA for 10 minutes and stained for the presence 
of LYVE-1+ lymphatic vessels (red), Langerin cells (green) and CCL21 (blue).  Sections were then 
counterstained with DAPI and mounted using ProLong Gold.  Images were taken using the Zeiss LSM 510 
confocal microscope.  N=3 per group for tumour bearing lymph nodes.  N=2 per group for non-tumour 
bearing lymph nodes.   
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Figure 4.9: CCRL1 Expression is Downregulated in the Sinus of Tumour Bearing Lymph Node 
Sections. 
 
Representative images of inguinal lymph node sections taken from WT and CCRL1-KO C57BL/6 
mice.  Mice received 1x105 CCR7-expressing B16-F1 melanoma cells via subcutaneous injection.  
Mice were sacrificed after 3 weeks and serial lymph node sections cut and frozen.  Frozen sections were 
fixed in 4% PFA for 10 minutes and stained for the presence of LYVE-1+ lymphatic vessels (red), 
Langerin cells (green) and CCL21 (blue).  Sections were then counterstained with DAPI and mounted 
using ProLong Gold.  Images were taken at 25x magnification using the Zeiss LSM 510 confocal 
microscope.  N=7 per group for WT lymph nodes.  N=3 per group for CCRL1-KO lymph nodes.   
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Figure 4.10: PCR Genotyping of CCRL1 Genomic DNA. 
 
PCR genotyping of ear-punch genomic DNA obtained from WT (+/+), CCRL1-heterozygous (+/-) and 
CCRL1-homozygous KO (-/-) mice.  a) Ear-punch tissue was lysed using PCR lysis buffer at 95°C for 20 
minutes.  The lysis buffer was inactivated upon the addition of PCR neutralizing buffer and the lysed tissue 
was centrifuged briefly before being PCR amplified.  PCR products were separated by agarose gel 
electrophoresis using a 1.5% agarose gel and visualized using SYBR safe DNA gel stain.  b) Table 
summarising the genotype of each mouse. * = Mice selected for use in tumour experiment. 
* 
* 
* 
* 
* 
* 
* 
* 
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Figure 4.11: Optimisation of the Expression of Luciferase and CCR7 in the B16-CCR7 Cell 
Line. 
 
a) Optimisation of luciferase expression in B16-CCR7 cells.  Cells were seeded into a black-
walled 96-well tissue culture plate at a 1:2 titration with a starting concentration of 1x105 
cells/well both before and after selection with puromycin.  The cells were incubated overnight at 
37°C.  Prior to imaging, the media was aspirated and replaced with 100µl/well of D-Luciferin.  
The plates were imaged using the IVIS® Spectrum intravital microscope and analysed using the 
IVIS® Living Image software.  Region-of-interest (ROI) measurements were generated using the 
IVIS® Living Image software and exported to Microsoft Excel.  Graphs were generated by 
plotting the ROI values for each experimental condition against the cell count.  b) Optimisation 
of CCR7 expression in B16-CCR7 cells.  B16-F1, parental B16-CCR7 and geneticin-selected 
B16-CCR7 cells were seeded at 0.5x106 cells/well in to a clear, round-bottomed 96-well plate 
and then Fc-blocked for 10 minutes at 4°C before being stained using a PE-conjugated anti-
CCR7 antibody and near infrared cell death stain.  Immunostained cells were analysed using the 
Beckman Coulter CyAn™ ADP analyser and FlowJo software.  N=1  
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Figure 4.12: Expression of Luciferase by B16-CCR7 Cells Does Not Correlate With 
Tumour Size. 
 
a) B16-F1 and B16-CCR7 cells were harvested by trypsinisation and resuspended at 60x106 
cells/ml in cold PBS.  Cells were then passed through a 70µm strainer and the final concentration 
adjusted to 50x106 cells/ml.  For ear injections, 20µl of cell suspension was injected into the 
subcutaneous space under the central dorsal surface of the ears of both WT and CCRL1-KO 
C57BL/6 mice.  Mice were weighed and received D-Luciferin via i.p. injection (10µl per kg 
body weight).  After 5 minutes, the mice were anaesthetised with 2.5% isoflurane and then 
imaged using the IVIS® Spectrum intravital microscope.  b) ROI measurements were generated 
using the IVIS® Living Image software and exported to Microsoft Excel.  Tumour diameter and 
radius was also measured using a caliper and graphs generated by plotting the ROI values against 
tumour diameter or radius.  N=1.  
 
 57 
5. DISCUSSION 
   Metastasis is the major cause of death from cancer.  It is a highly complex process 
and despite much progress, the molecular mechanisms underlying tumour metastasis 
remain elusive.  As such, a better understanding of the mechanisms by which tumour 
cells traffic to secondary organs is warranted and may help inform the development of 
more targeted therapies to improve patient prognosis.  In recent years, a role for 
chemokine receptors and their chemokine ligands in tumour growth, survival and 
metastasis has been suggested.   Expression of CXCR4 and its cognate ligand 
CXCL12, for example, have been associated with enhanced migration and metastasis 
(33).  Consistent with this, elevated CXCR4 expression has been demonstrated in 
breast tumours and their metastases (34).  In addition, CCR7 has been found to be 
highly expressed in metastatic breast cancer (34). 
   CCR7 is primarily involved in regulating the homing of leukocytes to LNs.  It also 
plays a prominent role in immune cell positioning within LNs.  Mice deficient in 
CCR7 display a strong reduction in LN cellularity as a result of impaired T cell and 
DC migration (20,23).  Immobilisation of its chemokine ligands, CCL19 and CCL21, 
on the apical surface of inflamed endothelium induces significant PBL arrest and 
transmigration, providing further evidence for CCR7-involvement in leukocyte homing 
(16).  
   Interestingly, the lymphatic invasion and subsequent migration of melanoma tumour 
cells towards the SLN bears many similarities with the normal trafficking of antigen-
bearing DCs to regional draining LNs.  Indeed, several lines of evidence exist that 
implicate CCR7 in metastasis to LNs (1,10,25-28).  On the other hand, relatively little 
is known about the contribution of CCRL1 or how its expression affects the axis role 
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of CCR7-CCL19/21 in LN metastasis.  In this present study, we investigated CCR7-
driven metastasis and survival in the LN and examined whether host CCRL1 
expression affects these processes. 
   Using the immunohistochemical staining method developed during initial 
experiments, we present the novel finding that CCR7-expressing B16 melanoma (B16-
CCR7) preferentially establishes within the B cell areas of the LN. Individual B16-
CCR7 cells were also identifiable within the sinus, however some were found to be 
both TRP-2+ and CD45+.  These possibly represent activated DCs or macrophages that 
are presenting processed TRP-2 peptides on their surface.  The significance of the 
above finding is not fully clear as the role of B cells in melanoma metastasis has not 
been extensively studied.  It may be that the B cells provide survival factors or 
protection from the otherwise harsh environment of the LN.  Large numbers of 
peritumoural B cells have been documented in primary melanoma (35).  Furthermore, 
high B cell numbers were associated with a significant survival advantage (35).  
   Alternatively, B cells may impair T cell-mediated anti-tumour immune responses.  
Effector-memory and IFNγ or TNFα-secreting CD4+ and CD8+ T cell activation and 
Ag-specific CD8+ T cell proliferation have been proposed to be impaired in tumour-
bearing mice lacking mature B cells (36).  Similarly, B cell-deficient mice display 
significant resistance to syngeneic B16 melanoma growth, as compared to WT mice 
(37); an observation thought to be a result of increased TH1 cytokine release and 
induction of CTL responses (37).  B cells may also promote tumour growth and 
survival by secreting B cell factors that induce chronic inflammation (38).  Melanoma 
tumour establishment in the LN did not appear to be affected by depletion of CCRL1. 
Further experiments are required to gain a better understanding of the role of B cells in 
metastatic melanoma growth and survival in the LN.  Depletion of B cells in both WT 
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and CCRL1-KO mice would provide detailed information about where, in the LN, 
these metastases, occur in the absence of B cells.   
   A number of CD45+ TRP-2- cells were identified within the tumour foci.  In an 
attempt to further characterise them, an array of antibodies raised against common 
immune cell markers were employed.  A large number of CD4+ cells were found to 
infiltrate the tumour – this was unchanged in CCRL1-KO mice.  These could 
potentially be CCR7+ lymphoid tissue inducer (LTi) cells.  Previously published data 
has shown that CD45+CD3ε-RORγt+ LTi cells are preferentially recruited to both WT 
and CCL21high melanoma tumours in a CCR7-dependant manner (39).  Further, LTi 
recruitment was associated with enhanced tumour growth as depletion of LTi cells 
impeded melanoma tumour growth (39).  Immunohistochemical staining for RORγt, in 
conjunction with CD45, CD3 and other known LTi markers, would be required to 
confirm this. 
   Further staining revealed that melanoma metastasis may suppress CCL21 and 
CCRL1 expression in the LN sinus.  ACRs are believed to mediate the transcytosis of 
chemokines and their concentration at particular sites (17).  Loss of CCRL1 may, 
therefore, result in reduced expression of CCL19 and CCL21 in the sinus.  
Downregulation of CCL21 at the sinus has been reported before (28) and could be a 
potential mechanism to suppress the recruitment of DCs and T cells.  Of note, CCL21 
was found to be present in the tumour.  This is most likely CCL21-binding to the 
CCR7 receptors present on the tumour cells rather than secretion of CCL21 by the 
tumour cells, as they have been characterised as being CCL21-.  CCL21 has been 
reported to be present in melanoma tumours and is purported to be associated with the 
induction of an immunotolerant microenvironment(39).  Further work would involve 
using more quantitative methods to analyse CCL21 and CCRL1 expression in the LN.  
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A possible method would involve laser capture microdissection (LCM) of the LN 
marginal sinus followed by Western blotting or PCR. 
   As the majority of LNs displayed well-established metastases, it was not possible to 
examine the kinetics of tumour growth and the effect of CCRL1 expression in early 
LN metastasis in vivo.  In order to address this, B16-CCR7 cells were injected into the 
ears of WT and CCRL1-KO mice.  Interestingly, WT mice developed primary tumours 
at the site of inoculation with delayed kinetics when compared with CCRL1-KO mice, 
suggesting that depletion of CCRL1 markedly enhances tumour growth.  The size of 
the tumours were determined and mice were then imaged using the IVIS Spectrum® 
intravital microscope to evaluate the sensitivity of the B16-CCR7 cell line.  Tumour 
size was found not to correlate with luciferase activity.  A possible reason for the lack 
of luciferase activity in the largest of the tumours could be that this particular tumour 
had a much larger necrotic focus, with relatively few viable cells.  Alternatively, the 
cell line might be heterogeneous in its expression of luciferase.  Future work would, 
therefore, involve further optimisation of the cell line.  Superinfection of the luciferase 
vector, followed by long-term antibiotic selection should be performed. 
   In summary, CCR7-expressing B16 melanoma preferentially establishes in the B cell 
areas of the LN and suppresses both CCL21 and CCRL1 expression in the marginal 
sinus, possibly to limit the recruitment of DCs and T cells.  Depletion of CCRL1 did 
not appear to affect tumour growth and survival in the LN.  CCRL1-deficient mice did, 
however, develop tumours with enhanced kinetics when compared to WT mice.  
Future work will help to further unravel the roles of CCR7 and CCRL1 in melanoma 
metastasis. 
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7. APPENDIX A: Information on CCRL1 Primers 
 
 
Table 1.  The Primer Sets Used for Genotyping. 
 
Primer Primer Sequence (5’-3’) 
11com5 
(common) 
TGC TGG TGA GCT CTG GGT TC 
3IRES 
(knockout) 
CCC TAG ATG CAT GCT CGA CG 
(homologous to sequence in the inserted construct) 
11wt5 
(wildtype) 
AAT CGC CAC AAC TAC GGA GTT C 
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ABSTRACT 
Background:  DNA damage checkpoints are essential for the suppression of genome 
instability, one of the main driving forces of tumour progression.  The tumour 
suppressor, p53, is indispensible for the repair of damaged DNA and, as such, is tightly 
regulated.  Pituitary tumour transforming gene 1 (PTTG1)-binding factor (PBF), a 
poorly characterised proto-oncogene, and Rad6, an E2 ubiquitin ligase, have both been 
reported to regulate p53 stability and function.  Furthermore, Rad6 expression appears 
to be induced by overexpression of PBF. 
Aims:  The main objective was to investigate whether oncogenic levels of PBF 
promote p53 turnover through Rad6 activity.  Further research involved determining 
whether Rad6 expression is altered in thyroid cancer. 
Methods: Western blotting and Taqman RT-PCR were used to assess the level of PBF, 
Rad6 and p53 expression in thyroid cancer cell lines and in matched human normal 
and thyroid cancer specimens.  Co-immunoprecipitation assays were performed to 
determine whether Rad6 and PBF physically interact. 
Results: PBF directly binds to Rad6 and may regulate p53 stability and function via 
this interaction.  In addition, Rad6 expression is induced in thyroid cancer and appears 
to positively correlate with PBF expression.   
Discussion: The report demonstrates a potential mechanism by which PBF may be 
regulating p53 stability. 
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ABBREVIATIONS 
ATC – Anaplastic thyroid cancer 
BCA – Bicinchoninic acid 
DIT – Diiodotyrosine 
E1- Ubiquitin-activating enzyme 
E2 – Ubiquitin-conjugating enzyme 
E3 – Ubiquitin-ligase 
FTC – Follicular thyroid cancer 
MDM2 – Mouse double minute protein 2 
MIT – Monoiodotyrosine 
NIS – Sodium iodide symporter 
NLS – Nuclear localisation signal 
PBF – PTTG-binding factor 
PBF-Tg – transgenic mouse model of PBF overexpression 
PCNA – Proliferating cell nuclear antigen 
PTC – Papillary thyroid cancer 
PTTG – Pituitary tumour transforming gene 
T3 – 3,5,3’-triiodothyronine 
T4 – Tetraiodothyronine 
Tg – Thyroglobulin 
UBE2A – Rad6A 
UBE2B – Rad6B 
WT – Wild-type 
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1. INTRODUCTION 
1.1. The Thyroid Gland 
   The thyroid gland is a butterfly-shaped endocrine organ (figure 1.1).  It is situated in 
the neck, anterior to the larynx and is composed of 2 lateral lobes connected by a 
narrow section, known as an isthmus(40).  Histological examination reveals 3 
distinctive features of the thyroid – thyroid follicles, thyroid follicular cells and 
parafollicular C cells(40). The follicles form the main structural component of the 
thyroid and consist of a single layer of follicular cells enclosing a colloid-filled cavity 
(containing the thyroid hormone precursor, thyroglobulin (Tg)).  Parafollicular C cells 
are also present within this monolayer and are responsible for the production of 
calcitonin (40). 
 
    
    
   
The primary function of the thyroid is to produce and secrete the thyroid hormones, 
Figure 1.1: The Thyroid Gland 
 
The thyroid gland is a butterfly-shaped organ.  It is located at the back of the neck, anterior to 
the larynx.  It is composed of two lateral lobes that are connected by an isthmus. 
 
Figure taken from Macmillian Cancer Support, The Thyroid Gland – Cancer Information.  Available at: 
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Thyroid/Aboutthyroidcancer/Thethyroidgland.aspx. Last updated 1st 
April 2010 
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tetraiodothyronine (T4) and 3,5,3’-triiodothyronine (T3).  Synthesis of these hormones 
is primarily carried out by the follicular cells and is dependent on the presence of 
iodine, either obtained through the diet or via deiodinisation of T4 in the bloodstream 
(40).  Iodine is actively transported into the lumen by the sodium iodide symporter 
(NIS) and linked to tyrosine residues on Tg to generate the thyroid hormone 
precursors, monoiodotyrosine (MIT) and diiodotyrosine (DIT) (40).  These iodinated 
tyrosine residues subsequently combine to form T4 and T3, which bind to intracellular 
receptors to modulate the transcription of a number of genes (40). 
1.2. Thyroid Carcinoma 
   Thyroid carcinomas are one of the most common endocrine malignancies, 
accounting for approximately 1% of all human cancers (40).  An estimated 213 000 
cases were diagnosed worldwide in 2008 (41), and whilst uncommon, the annual 
incidence, particularly that of papillary thyroid cancer, appears to be on the rise 
(42,43).  This, however, may reflect an increase in pathologic detection rather than a 
true increase in incidence (42).   
   Thyroid carcinomas are typically classified based upon their cellular origin.  
Carcinomas arising from thyroid follicular cells can be categorised as differentiated 
carcinomas or undifferentiated anaplastic thyroid carcinoma (ATC) (40,44).  Both 
Follicular (FTC) and papillary (PTC) thyroid cancer are examples of differentiated 
carcinomas and they comprise almost 80% of diagnosed cases (40). 
   Near-total or complete thyroidectomy, followed by post-operative 131I therapy 
constitutes the main treatment strategy (40).  Although thyroid cancer is associated 
with a favourable prognosis, as demonstrated by a 10-year survival rate of 93% and 
85% for PTC and FTC respectively (45), up to 35% of patients present with metastases 
and recurrent disease (45).  
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   Instability in the genome is a characteristic feature of almost all human tumours and 
is necessary to facilitate the acquisition of the several mutations required for tumour 
initiation and progression.  Indeed, thyroid cancer has been shown to display defects in 
genome maintenance and repair, for example, in the form of aneuploidy (46).   
1.3. The Tumour Suppressor p53 
   The tumour suppressor protein, p53 is possibly one of the most critical ‘cellular 
gatekeepers’ owing to its function in regulating cellular responses to DNA damage.  It 
is a sequence-specific transcription factor (47) and has been shown to transactivate a 
plethora of target genes via direct binding to upstream p53 response elements (47).  
These target genes encode for proteins that are involved in a diverse array of cellular 
responses, including cell cycle regulation, apoptosis, senescence, DNA repair and 
angiogenesis (47,48).  Under normal conditions, the levels of p53 are maintained at a 
low basal state.  By contrast, p53 stabilisation and activation is rapidly induced in 
response to aberrant growth, DNA damage and cellular stress (48). 
   Not surprisingly, dysregulation of p53 function has been implicated in the majority 
of human cancers and more than 50% of all malignancies are believed to harbour 
inactivating mutations of the p53 gene (48).  Interestingly, p53 mutations have been 
reported to occur late in tumour progression (49,50).  For example, such mutations are 
rarely observed in differentiated thyroid cancer but have been reported in 
approximately 55% of ATCs (44). 
   The stability of p53 is tightly regulated by post-translational modification, more 
specifically via ubiquitination by the ubiquitin-proteasome degradation pathway (47).  
Ubiquitination of a protein requires 3 distinct enzymes; a ubiquitin-activating enzyme 
(E1), a ubiquitin-conjugating enzyme (E2) and an E3 ubiquitin-ligase (E3) (51).  
Activation of ubiquitin is achieved through a covalent thioester bond with E1 (51).  
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The activated ubiquitin is then actively transferred to E2, which then acts in concert 
with E3 to attach the ubiquitin to one or more lysine residues on the target protein (51).  
Monoubiquitination is thought to regulate protein localisation and membrane transport 
(51).  Further ubiquitination is required for the efficient recognition and subsequent 
proteasomal degradation of the target protein (51). 
   The E3 ligase, mouse double minute protein 2 (MDM2) is purported to be the key 
regulator of p53 turnover (47).  Not only does it facilitate the ubiquitination and 
degradation of p53, but also sterically hinders the transactivation domain, which is 
required for p53 transcriptional activity (47).  Recent evidence suggests that other 
proteins may also be involved in regulating p53 stability and degradation 
independently of MDM2 (51-54). 
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1.4. PTTG1-Binding Factor 
   Pituitary tumour transforming gene 1 (PTTG1)-binding factor (PBF) is a poorly 
characterised protein that was initially discovered as a result of its ability to associate 
with the human securin, PTTG1 (55).  The PBF gene is located within the 
chromosomal region 21q22.3 and encodes a 180 amino acid protein with a predicted 
molecular mass of 22 kDa (55).  Of note, the peptide sequence appears to share no 
significant homology with any other human protein and is highly conserved across 
many animal species, thus signifying evolutionary importance and unique function 
(56).  Initial evidence from protein prediction studies led to speculation that PBF was a 
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Figure 1.2: p53 Levels Are Regulated by MDM2 
 
p53 levels rise in response to certain physiological stimuli (not shown) and bind to the 
promoter regions of a large number of target genes whose transcription it induces.  One of the 
genes induced is MDM2 and this results in an increase in the level of MDM2 protein.  MDM2 
then binds to p53, which is exported from the nucleus and is ubiquitinated.  Ubiquitination 
promotes the proteasomal degradation of p53.  This negative feedback-loop ensures that p53 
levels return to their usually low basal state. 
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cell membrane glycoprotein, however, the subsequent identification of bipartite 
nuclear localisation signal (NLS) suggests that PBF may also represent a nuclear 
protein (55,56). 
   It is well established that expression of PBF is ubiquitous (55).  Nevertheless, 
relatively little has been reported with regards to its function.  It has previously been 
demonstrated to facilitate the nuclear transport of PTTG1 (55).  PTTG1 is believed to 
function as a proto-oncogene, regulating diverse cellular processes, such as cell cycle 
progression and DNA repair (46).  All functions ascribed to PTTG1 require nuclear 
localisation; in this context PBF may play an indirect role in tumourigenesis (55).  
Recent evidence suggests that PBF may also be directly implicated in tumourigenesis 
as subcutaneous expression induces the formation of tumours in nude athymic mice 
(57). In support of this, altered PBF expression has been noted in a number of cancers, 
particularly that of the thyroid (56-59).  In breast cancer, PBF overexpression and 
secretion was found to induce cell invasion (58).  Several studies have also highlighted 
a role of PBF in sodium iodide symporter (NIS) regulation in the thyroid (60,61).  
Overexpression of PBF resulted in repression of NIS function, both in vitro and in vivo 
and induced significant hyperplasia within the thyroid (56,60-62).  When taken 
together, these observations suggest PBF is a multifunctional proto-oncogene.  
However, the precise contribution of PBF in tumourigenesis remains elusive. 
   Recently, PBF has been identified as a novel regulator of p53 function (54).  
Oncogenic levels of PBF were found to induce a significant reduction in the half-life of 
p53, a finding that was correlated with increased p53 ubiquitination and repression of 
p53-mediated gene transactivation (54).  Subsequent co-immunoprecipitation assays 
confirmed a direct interaction between PBF and p53(54).  Consistent with this, p53 
function was impaired in a transgenic mouse model of PBF overexpression (PBF-Tg) 
 77 
(54).  Gross genetic instability was also evident in PBF-Tg mice, as indicated by 
elevated levels of DNA repair genes, such as Rad6(54).  Further, PBF, p53 and Rad6 
expression were altered in matched human colorectal tumours, with p53 expression 
negatively correlating with both PBF and Rad6 expression(54).  
1.5. The E2 Ubiquitin-Conjugating Enzyme, Rad6 
   Rad6 belongs to a group of E2 ubiquitin-conjugating enzymes primarily involved in 
DNA damage repair(63).  In humans, the Rad6 gene is duplicated and, as a result, 
encodes for 2 proteins – Rad6A and Rad6B (95% sequence homology) (63).  Both 
genes are highly conserved among eukaryotes and are known to be expressed in all 
tissues of the body(63).  Rad6 interacts with 3 different E3 ubiquitin ligases in order to 
carry out the numerous functions ascribed(64).  For example, association with Ubr1 
promotes the degradation of target proteins through the N-end rule(64).  Alternatively, 
the formation of a Rad6-Rad18 heterodimeric complex results in the ubiquitination of 
proliferating cell nuclear antigen (PCNA), which mediates post-replication DNA 
repair(64).  Rad6 may also interact with Bre1, and potentially Lge1, to regulate gene 
transcription(65) through ubiquitination of the histone protein, H2B(66). 
   There is a growing body of evidence to suggest that Rad6 may also be implicated in 
the initiation and progression of many cancers.  For example, overexpression has 
previously been documented in breast cancer (67).  Rad6 has also been implicated in 
the regulation of p53 stability and function (52,53).  In support of this, Rad6 has been 
shown to physically interact with p53 (51).  As both PBF and Rad6 expression has 
been negatively correlated with p53 expression and both proteins have been reported to 
independently regulate p53 levels, it will be important to determine whether PBF 
overexpression influences p53 turnover by modulating Rad6 activity. 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
 
Cell Lines 
• K1 human papillary thyroid carcinoma cell line acquired from the Health 
Protection Agency Culture Collections (HPACC). 
• TPC-1 human papillary thyroid carcinoma cell line obtained from Dr Rebecca 
Schweppe, University of Colorado, US. 
Human Tissue 
Matched normal and thyroid tumour tissue (N=11) was obtained from patients 
undergoing surgery at the University of Birmingham Queen Elizabeth Hospital, 
UK and stored at -80°C.  Normal specimens were taken from the contralateral lobe 
at the time of surgery and were shown to be non-cancerous upon histological 
examination.  All tissue samples were collected following local ethical approval 
and signed informed patient consent in accordance with the Declaration of 
Helsinki.  Of the 11 tissue samples, there were 9 cases of papillary carcinoma and 2 
cases of follicular carcinoma.   
Cell Culture 
• RPMI 1640 (- L-Glutamine) – Sigma-Aldrich, UK 
• Opti-MEM reduced serum media – Gibco, UK 
Antibodies 
• Rabbit polyclonal antibody to Rad6 – Abcam #Ab31917 
• Rabbit anti-human IGF-1 IgG – Biovision #5119-100 
• Polyclonal goat anti-rabbit IgG-HRP – Dako #P0448 
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• Polyclonal rabbit anti-mouse IgG-HRP – Dako #P0161 
• Mouse anti-β Actin – Sigma, UK #A3854 
• Rabbit anti-human PBF antibody – made in-house 
• P53 (DO-I) mouse monoclonal antibody IgG2a – Santa Cruz Biotechnology 
#SC-126 
• Mouse anti-fibrillarin 38F3 IgG – Abcam #Ab4566 
Taqman Gene Expression Assays 
• Human PTTG1IP gene expression assay – Applied Biosystems #4351372 
• Human UBE2A gene expression assay – Applied Biosystems #4331182 
• QuantumRNA™ classic 18S internal standard – Applied Biosystems 
#AM1716M 
Buffers and Solutions 
• Blocking Solution: 5% w/v milk powder in TBST 
• TBST: 1M tris pH 7.6, 5mM sodium chloride, tween-80 and dH20 
• RIPA Lysis Buffer: tris-HCl pH 7.4, sodium chloride, igepal, 10% sodium 
deoxycholate, 100mM EDTA and dH20 
• Gel Sample Buffer: 10% w/v DTT in laemlli buffer 
• 5% Stacking Gel: 0.8M tris-HCl pH6.8, 40% polyacrylamide, 10% SDS, 10% 
APS, TEMED and dH20 
• 12% Resolving Gel: 1.5M tris-HCl pH8.8, 40% polyacrylamide, 10% SDS, 
10% APS, TEMED and dH20 
• 10x Running Buffer: tris base, glycine, SDS and dH20.  Dilute to 1x in dH20 
• Transfer Buffer: tris base, glycine, methanol, SDS and dH20 
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Additional Materials 
• Penecillin-streptomycin – Gibco, UK #15070-063 
• DL-Dithiothreitol (DTT) – Sigma, UK #D9779-10G 
• Phosphate buffered saline (PBS) tablets – Sigma, UK #P4417-100TAB 
• Tween-80 – Sigma, UK #P4780 
• Protogel – National Diagnostics, US - #EC-891 
• Methanol – VWR, UK #20847.307 
• Trypsin/EDTA – Invitrogen, UK #15400-054 
• UBE2B silencer® select siRNA – Ambion, UK #4390824 
• UBE2A silencer® select siRNA – Ambion, UK #4390825 
• Silencer® negative control siRNA – Ambion, UK #AM4635 
• Lipofectamine™ 2000 reagent – Invitrogen, UK #52887 
• FuGene®6 transfection reagent – Roche, UK #11988387001 
• Human UBE2A pCMV-XL5 cDNA clone – OriGene, US #SC109859. 
• Precision plus protein dual colour standards – Biorad, US #161-0374 
• Laemmli sample buffer – Biorad, US #161-0737 
• Amersham ECL plus western blotting detection system – GE Life Sciences, 
UK #RPN2132 
• Pierce® ECL2 western blotting substrate – Thermo Scientific, UK #P180197 
• Trizma base – Sigma, UK #T1503 
• Glycine – Sigma, UK #G8898 
• TEMED – Sigma, UK #T9281 
• Sodium chloride – Fischer Scientific, UK #S/3160/65 
• Medical X-ray film – Kodak, US #8143059 
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• Sodium dodecyl sulphate (SDS) – Sigma, UK #L4390 
• Ammonium persulphate (APS) – Sigma, UK #A3678 
• Pierce® BCA assay – Thermo Scientific, UK #23227 
• RNeasy mini kit – Qiagen, US #74104 
• 2x GoldStar TaqMan PCR mastermix – Eurogentec, US #RT-QP2X-03+QGS 
• Reverse transcription system – Promega, US #A3500 
• AMV reverse transcriptase – IBR Stores, UK #M9004 
• Random primers – IBR Stores, UK #C1181 
• Protease inhibitor cocktail – Sigma, UK #P8340 
• Foetal Calf Serum – Sigma, UK #10437-028 
• Amersham Hybond P PVDF membrane – GE Life Sciences, UK #RPN303F 
• Protein-G sepharose 4 fast flow – GE Life Sciences, UK #17-0618-01 
2.2. Methods 
2.2.1. Cell Culture 
   TPC-1 and K1 cells were routinely cultured in RPMI 1640 media supplemented 
with 10% FCS, penicillin and streptomycin.  Cell cultures were incubated at 37°C 
in a humidified atmosphere containing 5% CO2 until confluent.  Cells were then 
detached using 0.25% trypsin/EDTA for 5 minutes at 37°C and harvested in 10-
20ml of complete media.  For transfection experiments, K1 cells were seeded at 
1x105 cells per well and TPC-1 cells at 7.5x104 cells per well into clear, 6-well 
tissue culture plates.  For co-immunoprecipitation, K1 and TPC-1 cells were 
seeded at 2.5x105 cells and 1.875x104 cells, respectively, in 5ml into vented 25cm3 
tissue culture flasks.  For routine cell culture maintenance, a 1:10 (K1) or 1:20 
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(TPC-1) dilution was carried out and the appropriate volume of cell suspension 
transferred to a vented 75cm3 tissue culture flask containing pre-warmed media. 
2.2.2. Transient Transfection of K1 and TPC-1 Cells 
2.2.2.1. siRNA-induced Knockdown 
   K1 and TPC-1 cells seeded onto 6-well tissue culture plates were left to adhere 
overnight at 37°C in a CO2 incubator.  Cells were then transfected with either 
UBE2A+B siRNA or negative control siRNA at an optimal siRNA: 
Lipofectamine™ ratio of 1µl siRNA to 6µl of Lipofectamine™.  Prior to 
transfection, Lipofectamine™ was diluted in opti-MEM and incubated at room 
temperature for 5 minutes.  After the 5-minute incubation, the siRNA (40nM) was 
combined with the diluted Lipofectamine™ and incubated for a further 20 minutes 
to enable complex formation.  The media was then aspirated from the wells of 
each tissue culture plate and replaced with 1ml/well of the transfection mix, after 
which, the cells were incubated at 37°C in a CO2 incubator for 48 hours.  The 
media was replaced with complete growth media 4-6 hours post-transfection. 
2.2.2.2. Overexpression 
   K1 and TPC-1 cells seeded in 6-well tissue culture plates were left to adhere 
overnight at 37°C + 5% CO2.  The cells were then transfected using the Fugene® 6 
transfection reagent according to the manufacturer’s protocol.  The optimal 
Fugene:DNA ratio was determined to be 3µl Fugene® per 1µg of plasmid DNA.  
Preparation of the complex involved diluting the Fugene® in opti-MEM and 
allowing the mixture to incubate at room temperature for 5 minutes.  The plasmid 
DNA (2µg per well) was added to the mixture and left to incubate at room 
temperature for 20 minutes.  100µl of this transfection mix was then added in a 
drop-wise manner to each well, after which the plates were left to incubate for 48 
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hours at 37°C in a CO2 incubator.  For transfection of 25cm3 tissue culture flasks, 
250µl of the transfection mix was added to each flask (5µg plasmid DNA per 
flask). 
2.2.3. Protein Extraction 
   Whole cell lysates were harvested in 250µl/well of RIPA lysis buffer containing 
protease inhibitors after a 20-mintue incubation at -20°C.  Prior to loading, the 
protein concentration was measured by the Bicinchoninic acid (BCA) assay, using 
bovine serum albumin (BSA) as a standard.  Lysates were then diluted to the 
appropriate concentration and solubilised using laemlli buffer containing 10% DTT 
at 95°C for 5 minutes.  Samples were used immediately or stored at -20°C. 
2.2.4. Western Blotting 
   Western blot analysis was performed by SDS-PAGE.  Soluble protein samples 
were loaded onto 12% SDS-polyacrylamide gels, alongside a molecular weight 
marker, and electrophoresed at 140V.  Once the proteins were fully separated, the 
gels were placed with PVDF membrane in a blot cassette, which was then run at 
360mA for approximately 75 minutes to allow transfer of the proteins to the PVDF 
membrane.  The membranes were incubated at room temperature in 5% milk in 
TBST for 1 hour with gentle shaking and followed by an overnight incubation with 
the primary antibody diluted in 5% milk in TBST at 4°C with gentle shaking.  The 
membranes were washed 3 times with TBST for 10 minutes before incubation with 
the secondary antibody diluted in 5% milk in TBST for 1 hour at room 
temperature.  The membranes were again washed 3 times in TBST for 10 minutes 
and developed by treatment with ECL plus followed by exposure on x-ray film.  
The x-ray film was developed using the Xograph Compact X4 x-ray film 
processor. 
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2.2.5. Co-immunoprecipitation Assays 
   K1 and TPC-1 cells transiently transfected with either pcDNA3 (vector only), 
PBF or UBE2A were harvested in 350µl of RIPA buffer containing protease 
inhibitors.  After a brief sonication, cell lysates were centrifuged at 12000G for 10 
minutes at 4°C.  The lysate was transferred to a clean eppendorf and 35µl removed 
for use as a whole cell lysate sample.  Each lysate was incubated with 30µl of 
beads prepared from protein-G sepharose 4 fast flow for 2 hours at 4°C with 
rotation.  The lysates were then pulse centrifuged at 6000rpm for 30 seconds and 
the supernatant transferred to a clean eppendorf.  Each lysate was incubated with 
15µl of rabbit anti-PBF antibody or mouse anti-p53 antibody at 4°C overnight with 
rotation.  Control samples were incubated without antibody, with a rabbit anti-
IGF1 antibody or a mouse anti-fibrillarin antibody.  The samples were further 
incubated with 30µl of bead slurry prepared from protein-G sepharose 4 fast flow 
beads for 3-4 hours at 4°C with rotation.  The sepharose beads were then pulse 
centrifuged to remove any unbound protein and washed a further 6 times in 500µl 
of RIPA buffer.  Any bound protein was then eluted in 30µl of laemmli buffer 
containing 1% SDS and 5% 2-β mercaptoethanol at 37°C for 30 minutes.  The 
proteins were separated by SDS-PAGE following the western blotting protocol 
outlined above (ref: 3.2.4. Western Blotting). 
2.2.6. Protein and RNA Extraction From Matched Normal 
and Tumour Tissue 
   Whole cell protein extracts from matched normal and thyroid cancer tissues were 
prepared in RIPA buffer containing protease inhibitors using a rotor-stator 
homogeniser.  The protein concentration for each sample was determined by BCA 
assay, using BSA as a standard.  Samples were then diluted to the appropriate 
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concentration before being separated by SDS-PAGE, as described previously (ref: 
3.2.3. Protein Extraction and 3.2.4. Western Blotting). 
   Total RNA was extracted from the tissues using the RNeasy Mini kit (Qiagen), 
following the manufacturer’s guidelines.  The RNA was reverse transcribed using 
the avian myeloblastosis virus (AMV) Reverse Transcription System (Promega).  
Firstly, 0.5µg of total RNA was diluted in RNase-free water and incubated at 70°C 
for 10 minutes.  A reverse transcription master mix was then prepared and 
combined with each RNA sample before being incubated for a further 10 minutes 
at room temperature.  The samples were then PCR amplified (42°C – 1 hour, 95°C 
– 5 minutes, 4°C – 5 minutes), pulse spun and stored at -20°C after the addition of 
10µl of RNase-free water. 
2.2.7. Quantitative PCR 
   The expression of PBF and UBE2A mRNA was determined by quantitative PCR 
using the ABI PRISM 7700 Sequence Detection System.  The PCR reaction was 
conducted in 96-well PCR plates.  A 1µl aliquot of each cDNA sample was added 
to a 24µl master mix containing 2x TaqMan universal PCR master mix, a TaqMan 
gene expression assay (PBF/UBE2A or 18S) and RNase-free water, giving a total 
reaction volume of 25µl.  The target gene probes were labelled with FAM and the 
18S rRNA probe with VIC.  The PCR reaction was as follows: 
1. 50°C – 2 minutes 
2. 95°C – 10 minutes 
3. Then 40 cycles of 95°C for 15 seconds 
4. 60°C – 1 minute 
2.2.8. Data Analysis 
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   Data are displayed as mean ± SEM.  Normally distributed data was statistically 
analysed using a two-tailed Student’s t-test unless otherwise stated.  A P value of 
<0.05 was considered to be statistically significant.  
 
3. AIMS AND OBJECTIVES 
   The main objective was to investigate whether oncogenic levels of PBF promote 
Rad6-mediated p53 turnover in the papillary thyroid cancer cells, K1 and TPC-1.  
Further research involved characterising Rad6 expression in human matched normal 
and thyroid cancer specimens, in conjunction with PBF and p53 expression. 
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4. RESULTS 
4.1. Rad6 Appears to Regulate the Expression of PBF and 
p53 in K1 and TPC-1 Cells 
   To determine the relationship between Rad6, PBF and p53, we first assessed the 
effect of Rad6 overexpression on PBF and p53 protein expression.  These experiments 
were performed in 2 human papillary thyroid cancer cell lines, K1 and TPC-1, both of 
which express WT p53.  As shown in figure 4.1, transient transfection of K1 cells with 
Rad6 resulted in a reduction in endogenous expression levels of p53 and a marginal 
decrease in PBF expression, when compared to control-transfected cells.  In contrast, 
depletion of Rad6 expression by siRNA was associated with increased expression of 
endogenous PBF (data not shown) and p53.  Similar results were also observed in 
TPC-1 cells, although depletion of Rad6 appeared to result in reduced levels of p53 
protein (figure 4.2).  These results suggested that Rad6 may potentially be involved in 
the regulation of both PBF and p53 protein expression. 
4.2. Co-Immunoprecipitation of Rad6 by p53 and PBF In 
Vitro 
   To further investigate an association between PBF and Rad6, endogenous co-
immunoprecipitation experiments were performed using protein lysates prepared from 
TPC-1 cells transfected with PBF, Rad6 or empty vector.  Consistent with previous 
findings(53), co-immunoprecipitation with an anti-p53 antibody revealed that Rad6 
specifically interacts with p53 (figure 4.3).  In addition, further co-
immunoprecipitation assays using an anti-PBF antibody revealed a novel interaction 
between Rad6 and PBF (Figure 4.4).  After immunoprecipitation of endogenous PBF, 
a band corresponding to Rad6 was detectable in lysates from Rad6-transfected cells but 
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not in cells transfected with PBF.  This provided further support for a role of Rad6 in 
PBF regulation of p53 and raised the question of whether Rad6 levels were altered in 
cancer, as has been noted for PBF and p53. 
4.3. Correlation Between Rad6 and PBF mRNA Expression 
in Matched Normal and Thyroid Cancer Tissue 
   Although PBF overexpression has been demonstrated in a number of cancers (56-
59), Rad6 induction has only been documented in breast and colorectal cancer (54,67).  
Matched human normal and thyroid cancer specimens were therefore analysed to 
determine the endogenous expression levels of Rad6.  The samples were also assessed 
for PBF and p53 expression to determine if there was any correlation with Rad6 
expression in vivo.  
   Protein expression was quantified by western blotting (figure 4.5b).  However, due to 
technical issues, β-actin expression could not be quantified.  Protein concentrations 
were calculated twice, in triplicate, using the BCA assay and the BSA protein 
standards appeared to be accurate as demonstrated in figure 4.5a.  Furthermore, 
coommassie staining of the PVDF membranes confirmed equal protein loading (not 
shown).  9/11 (82%) tumours demonstrated induced PBF expression (figure 4.5b), with 
a ~3-fold induction compared to matched normals (figure 4.6, P=0.02).  7/11 (64%) 
tumours also displayed upregulation of Rad6 expression (figure 4.5b), with a ~1.8 fold 
induction compared to matched normals (figure 4.6, P=0.02).  p53 was present at high 
levels in 1 of 11 tumours and at lower levels in 6 others (figure 4.5b). 
   Rad6 and PBF mRNA expression was also examined in these samples by Taqman 
RT-PCR.  A similar, albeit, non-significant trend was observed, with tumours 
demonstrating a ~2-fold increase in Rad6 mRNA expression and a ~1.4-fold increase 
in PBF mRNA expression (figure 4.7a).  In addition, a significant positive correlation 
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was identified between PBF and Rad6 mRNA expression (figure 4.7b/c, rs=0.9).  In 
summary, the results show that Rad6 physically interacts with PBF, suggesting the 
possible involvement of Rad6 in PBF regulation of p53 function.  In addition, Rad6 
expression is induced in thyroid cancer and seems to correlate with PBF expression. 
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Figure 4.1: Rad6 Appears to Regulate the Expression of PBF and p53 in K1 Cells 
 
K1 cells, plated at 1x105 cells per well, were transfected with the indicated vectors or siRNAs and incubated at 
24h or 48h, respectively.  Whole cell lysates were then harvested and analysed by Western blotting with the 
indicated antibodies.  The intensities of Rad6, p53 and PBF were quantified and the expression levels relative to 
β-actin are shown.  Mean ± SEM.  n=1 for Rad6 knockdown.  n=2 for Rad6 overexpression.  
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Figure 4.2: Rad6 Appears to Regulate the Expression of PBF and p53 in TPC-1 Cells 
 
TPC-1 cells, plated at 7.5x104 cells per well, were transfected with the indicated vectors or siRNAs and 
incubated at 24h or 48h, respectively.  Whole cell lysates were then harvested and analysed by western blotting 
with the indicated antibodies.  The intensities of Rad6, p53 and PBF were quantified and the expression levels 
relative to β-actin are shown.  Mean ± SEM.  n=1 
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Figure 4.3: Co-Immunoprecipitation of Rad6 by p53 in vitro 
 
TPC-1 cells were transfected with the indicated vectors and incubated for 48h.  Whole cell 
lysates were then harvested and were subjected to co-immunoprecipitation of Rad6 with an anti-
p53 antibody.  Bound Rad6 was analysed by western blotting with an anti-Rad6 antibody.  (-): no 
transfection, (+): transfection, NAb: no antibody control, ISO: isotype control.   n=2 
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Figure 4.4: Co-Immunoprecipitation of Rad6 by PBF in vitro 
 
TPC-1 cells were transfected with the indicated vectors and incubated for 48h.  Whole cell 
lysates were then harvested and were subjected to co-immunoprecipitation of Rad6 with an anti-
p53 antibody.  Bound Rad6 was analysed by western blotting with an anti-Rad6 antibody.  (-): no 
transfection, (+): transfection, NAb: no antibody control, ISO: isotype control.   n=2 
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Figure 4.5: Altered Protein Expression in Matched Normal and Cancerous Thyroids 
 
a) The protein concentration of each extract was determined by BCA assay twice, prior to loading.  The 
protein standards are shown.  b) Whole protein extracts from human matched normal and thyroid 
tumour pairs were analysed by western blotting with the indicated antibodies. (N): normal, (C): cancer, 
n=11.  
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Figure 4.6: PBF and Rad6 Protein Expression in Normal and Cancerous Thyroids 
 
Protein extracts from human matched normal and thyroid tumour pairs were analysed by western 
blotting.  a) The intensities of PBF (n=9) and Rad6 (n=11) were then quantified and the 
expression relative to normal thyroid are shown.  Data presented as mean ± SEM.  b) 
Quantification of PBF (n=8) and Rad6 (n=10) protein expression relative to normal thyroid.  
Data presented as a scatter plot. NS: non-significant. 
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Figure 4.7: Correlation Between PBF and Rad6 mRNA Expression in Normal and Cancerous 
Thyroids 
 
a) PBF and Rad6 mRNA expression was determined by Taqman RT-PCR of RNA extracted from 
matched normal and thyroid cancer pairs.  Values were adjusted for 18S (housekeeping) gene expression 
and PBF (n=8) or Rad6 (n=10) mRNA expression in cancerous thyroids quantified relative to normal 
thyroid.  Data presented as a scatter plot. b) Quantification of PBF and Rad6 mRNA expression in thyroid 
cancer relative to normal thyroid.  Data presented as fold change in expression, (--): mean, n=11.  c) 
Correlation of PBF and Rad6 mRNA expression (fold change) in cancerous and normal thyroids.  
Statistics analysed using Spearman rank correlation, n=11. 
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5. DISCUSSION 
 
   DNA damage checkpoints, that enable cell cycle arrest and repair of damaged DNA, 
are absolutely essential for the suppression of genome instability, one of the main 
driving forces behind tumour progression (53).  The tumour suppressor, p53 is 
indispensible for the proper control of cellular responses towards DNA damage (68) 
and, as such, is typically regarded as the ‘guardian of the genome’.  Mutations in p53 
are frequently observed in human cancer (48).  Alterations in the post-translational 
modification of p53 through mutation or overexpression of key regulators, such as 
MDM2, are also implicated in the abrogation of p53 function in cancerous cells (69). 
   PBF has only been described in 16 publications to date and although it is 
ubiquitously expressed, its function remains elusive.  Previous work has revealed PBF 
to be a proto-oncogene.  It has been demonstrated to be overexpressed in thyroid 
(56,57,59), breast (58) and colorectal (54) cancer and is both transforming (in vitro) 
and tumourigenic (in vivo) (56).  In addition, PBF has recently been identified as a 
novel regulator of p53 stability and function, with which it physically interacts (54).  
Oncogenic levels of PBF induced the polyubiquitination and subsequent degradation of 
p53(54).  Furthermore, interaction with PBF prevented p53-mediated transactivation of 
downstream effectors, such as p21(54). 
   Rad6, an E2 ubiquitin ligase has also been implicated in the regulation of p53 (51-
53) and has been identified as an interacting partner(51,52).  Previous findings suggest 
that Rad6 is overexpressed in breast(67) and colorectal cancer(54).  Furthermore, 
expression appears to be induced by overexpression of PBF (54).  My current data now 
provides evidence of a potential role for Rad6 in PBF-mediated regulation of p53 in 
the papillary thyroid cancer cell lines, K1 and TPC-1.   
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   Knockdown of Rad6 led to the induction of PBF and p53 expression in K1 cells.  
Conversely, Rad6 overexpression resulted in a reduction in p53 protein expression as 
well as PBF, although modest.  Similar results were observed in TPC-1 cells.  These 
findings are in accord with previous data demonstrating that Rad6 negatively regulates 
p53(52).  Depletion of Rad6 resulted in the accumulation of p53, whereas 
overexpression led to rapid p53 ubiquitination and degradation(52).  Of note, these 
experiments were performed in Drosophila S2 cells and, thus, may not reflect what is 
happening in mammalian cells.  They must therefore be interpreted with caution.  
Indeed, Drosophila p53 (DMP53) and mammalian p53 are thought to be differentially 
regulated, as no MDM2 or p19ARF homologs have yet been uncovered in 
D.melanogaster(52).   
   The effect of Rad6 on p53 protein levels has recently been explored, by Chen et al, 
through depletion and overexpression of Rad6 in mammalian cells.  Interestingly, 
alteration of Rad6 expression had no effect on p53 protein levels (53).  A possible 
reason for the discrepancy could be that the papillary thyroid cancer cell lines 
potentially harbour mutations in the Rad6 gene resulting in altered protein function.  
Alternatively, abrogation of proteins involved in Rad6 or p53 regulation may also 
affect p53 expression.  MDM2, for example, has been reported to accumulate in the 
nuclei of certain classes of differentiated papillary thyroid cancer(70) and is required 
for Rad6-mediated p53 degradation(51).  Evidence suggests that Rad6 mediates the 
monoubiquitination of p53, whereas, further extension of the ubiquitin chain requires 
the presence of MDM2 in complex with Rad6 and p53(51).  In this instance, 
overexpression of Rad6, coupled with aberrant MDM2 expression or accumulation, 
could result in the polyubiquitination and subsequent degradation of p53.  Although 
the number of replicates was limited, when taken together, these results suggest that a 
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more complex relationship exists between PBF and Rad6 in the regulation of p53.  
Further repeats would be required to confirm these findings. 
   To further investigate the association between Rad6, PBF and p53, co-
immunoprecipitation assays were performed.  Both PBF and Rad6 have been shown to 
independently interact with p53 (51,54).  Co-immunoprecipitation for p53 confirmed 
that Rad6 and p53 do indeed physically interact.  Furthermore, co-immunoprecipitation 
for PBF identified Rad6 as a novel interacting partner.  Unfortunately, due to time 
constraints, the functional consequence(s) of such an interaction was not explored.  
Rad6 binding to PBF may be required for the recruitment of MDM2, which, as 
mentioned above, is required for efficient p53 degradation.  This is supported by 
preliminary findings that PBF directly interacts with MDM2 (Andy Turnell, 
unpublished data).  It is well known that PTTG1 binds to PBF at the C-terminal region, 
which contains the NLS motif (55).  This interaction is required for the nuclear 
localisation of PTTG1(55).  Similarly, Rad6 binding to PBF maybe localised to this C-
terminal region and may facilitate nuclear localisation of Rad6.  Once in the nucleus, 
Rad6 may then alter p53 transcription through modifications to local chromatin, as has 
been previously described (figure 5.1) (53).  Although the regions of Rad6 and PBF 
that are involved in the interaction remain to be determined, the data described 
represents the first study to report an in vitro association between Rad6 and PBF. 
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   It has previously been shown that PBF protein and mRNA levels are upregulated in 
thyroid cancer compared to normal thyroids(57), however Rad6 expression has never 
been explored, alongside PBF, in the thyroid.  In this study, expression of Rad6 and 
PBF were found to be significantly altered in human thyroid tumours compared to 
matched normal tissues. Protein expression of Rad6 and PBF was elevated in the 
majority of tumours compared to matched normals.  A similar trend was also observed 
for mRNA expression, although some differences between protein and mRNA 
expression were noted in the same samples.  This discrepancy may be due to technical 
difficulties associated with RNA extraction from tissue samples, or could be a result of 
RNA degradation post-extraction.  Interestingly, Rad6 mRNA expression was 
positively correlated with PBF mRNA expression, providing further support for our 
 
  
 
 
Nucleus 
Cytoplasm 
 
     
      
     
     
  
  
  
  
p53 
 
p53 target genes 
 
Rad6 
PBF 
p53 
Ubiquitin Proteasome 
Figure 5.1: Proposed Model of PBF Regulation of p53 Stability and Function via Rad6 
 
PBF binds to p53, possibly along with other binding partners such as Rad6 and MDM2, and 
induces the ubiquitination and degradation of p53 protein, thereby preventing transcription of 
p53 target genes.  PBF may also facilitate the nuclear transport of Rad6, thus enabling Rad6-
mediated modifications to local chromatin leading to altered p53 transcription. 
 MDM2 
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earlier in vitro observations.  This positive correlation has also been documented in 
colorectal tumours(54).  Of note, protein expression in these samples was not 
normalised to β-actin. If time had permitted, the PVDF membranes would have been 
probed for another housekeeping gene, such as GAPDH. 
In summary, the data outlined in this report provides evidence that the proto-oncogene 
PBF directly binds Rad6 and may regulate p53 function via this interaction. It also 
shows for the first time that Rad6 overexpression is frequent in thyroid cancer and that 
its expression appears to correlate with PBF expression.  Taken together, these 
observations have important implications, not only in our understanding of cancer 
biology and pathogenesis, but also in the use of oncogenes and tumour suppressors as 
prognostic indicators. 
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5.1. Future Work 
   First and foremost, further characterisation of the apparent complex relationship 
between Rad6, PBF and p53 is required.  Firstly, repeat experiments would need to be 
performed to confirm the effect of Rad6 expression on PBF and p53 expression in K1 
and TPC-1 cells.  PBF knockdown and overexpression should also be carried out to 
assess the influence of PBF on Rad6 and p53 expression. 
  Secondly, reciprocal co-immunoprecipitation experiments, where endogenous PBF is 
co-immunoprecipitated with an anti-Rad6 antibody, are needed to further prove 
binding of PBF with Rad6.  In addition, GST pull-down assays using PBF and/or Rad6 
mutants will facilitate in determining which regions are involved in binding.   
   Further protein and mRNA expression data is required, preferably using a larger 
number of matched normal and cancerous thyroid pairs.  Sequencing of the p53 gene 
in these samples would also prove useful and would allow for comparison of p53 status 
with protein expression.  Furthermore, if clinical details for each patient sample were 
available, Rad6 protein expression could be correlated with clinical outcome, thus 
providing information on the potential use of Rad6 expression as a prognostic indicator 
in thyroid cancer.  Immunohistochemical analysis of formalin-fixed paraffin embedded 
human thyroid tumour specimens for Rad6, p53 and PBF would provide additional 
information on expression of these proteins, including their localisation. 
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